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ABSTRACT 
 
Congenital hypothyroidism (CH) is the most frequent endocrinopathy in 
newborn. If not promptly treated lead to a severe impairment of psychomotor 
development. The etiophatogenesis of CH is still poorly understood; although 
several causative genes are identified, they can explain only a small portion of 
the pathological phenotypes. This scenario is further complicated if we focused 
on the incidence of CH in different context. In fact, epidemiological data indicate 
that children born prematurely have a 3-5 fold higher risk of CH. In addition 
premature infants born small for gestational age (SGA) have a risk of 12% higher 
to develop IC compared to prematures with appropriate development 
(AGA). The mechanisms that justify the increased risk of IC are still 
unknown. Some studies report that aberrant methylation patterns are associated 
with prematurity, intrauterine fetal development and the onset of some 
diseases. This project is focused on the study of DNA methylation, as 
predisposing factor to permanent thyroid dysfunction with neonatal onset. 
Using the Illumina Infinium-HumanMethylation27 technology we analyzed the 
global DNA methylation patterns (AVG) and selected the differentially 
methylated genes (DMGs) between 31 CH-cases born premature, AGA or SGA, 
and 28 term or preterm controls. To better understand the relationship between 
the DNA methylation and the premature birth, the intrauterine growth and the 
thyroid defect, the following groups were selected according to the gestational 
age at birth: 12 CH-with very preterm birth (CH-VPB<32wks) and 19 CH-with 
preterm birth (CH-PB 32-37wks); Controls: 9-CVPB, 6-CPB, 12-term birth 
(CTB>37wks). The same subjects were then analyzed according to intrauterine 
growth (20 CH-SGA, 11 CH-AGA than 6 C-SGA and 20 C-AGA) or the degree of CH: 
19 with overt CH (OH, TSH>10 U/L) and 12 with mild CH (MH, TSH<10 U/L) 
than 16 CPB and 12 CTB.  
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The global methylation analysis showed that infants born prematurely and SGA 
have a significant hypomethylation than term-controls. These data were 
confirmed by the gene-specific methylation analysis, through which we selected 
a large group of differentially methylated genes (DMGs) in CH-cases than term 
controls. Interestingly, the 95% of the DMGs are hypomethylated and the 70% of 
them are represented by CpG sites located in DNA non-coding regions. The gene 
ontology analysis revealed that genes involved in fetal growth and thyroid 
hormone metabolism were included among DMGs. The analysis of nine maternal 
genomic DNA for polymorphisms at the MTHFR revealed the possible association 
with folate deficiency during pregnancy and the global hypomethylation status of 
affected newborns. 
This is the first work exploring the role of epigenetic influences in the 
predisposition to congenital hypothyroidism. Our results suggest that genomic 
instability caused by global hypomethylation of non-coding regions may be 
related to premature birth and fetal growth delay. Under these conditions, 
thyroid defects are more frequent than expected and could result from the 
increased expression of predisposing genes, rather than from the reduced 
expression of protective genes. The role of maternal conditions during pregnancy 
seems to be a key factor to determine a proper DNA methylation pattern on 
fetus.  Based on the Developmental Origin of Health and Disease Theory, we can 
assume that adverse condition during pregnancy, such as folate deficiency, may 
produce a fetal epigenetic reprogramming and the adaptation of preterm 
neonate to the extrauterine life includes among other dysfunctions a thyroid 
functional impairment. If this data will be confirmed by further experiments, this 
could represent a new predisposing factor to take into account during pregnancy 
to prevent and improve the prenatal screening of CH. 
 
 
 
7 
 
INTRODUCTION-CHAPTER I 
1. THYROID GLAND DEVELOPMENT AND DEFECTS  
1.1 FETAL THYROID DEVELOPMENT: A BRIEF OVERVIEW 
 
The development of fetal thyroid function is dependent on the embryogenesis, 
differentiation and maturation of the thyroid gland. This is coupled with 
evolution of the hypothalamic-pituitary-thyroid axis and thyroid hormone 
metabolism, resulting in the regulation of thyroid hormone action, production 
and secretion [Fagman and Nilsson, 2011]. Thyroid hormones are critical for 
development of the fetal and neonatal brain, as well as for many other aspects of 
fetal growth. Before onset of function of its own thyroid gland, the only source of 
thyroid hormone for the fetus is the maternal thyroid gland [Panicker, 2011].  
1.1.1 Morphological aspects 
 
Thyroid gland is a composite of two different cell types, the follicular cells 
responsible for the production of thyroid hormones triiodothyronine (T3) and 
tiroxine (T4), and parafullicular C cells that produce calcitonin. Thyroid follicular 
cells (TFCs) are required to the thyroid fate from the endodermal epithelium of 
the foregut. C-cell precursors migrate from the neural crest to the fourth 
pharyngeal pouch located symmetrically on both sides of the neck (figure 1, 
panel A) [Fagman and Nilsson, 2010].  
Specification of these two cell types marks the beginning of the morphogenesis 
of the thyroid gland. The development of the thyroid, through anatomic studies 
in humans and genetic studies in mice, can be described generally in the 
following steps (figure 1, panel B) [Fagman and Nilsson, 2011]. In human, the first 
visible manifestation of the gland, the thyroid anlage begins as a thickening of 
the endodermal epithelium in the midline of the primitive pharynx at embryonic 
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day 20-22. Cellular proliferation of the TFC results in a thyroid bud that begins to 
migrate caudally from the pharyngeal floor leaving a remnant of descent known 
as the thyroglossal duct. The developing thyroid will pass through, or adjacent to, 
the hyoid bone on its course to the trachea the migration process nears 
completion by day 45. Under normal conditions the thyroglossal duct, which 
connects the thyroid to its pharyngeal origin, will disappear. Simultaneously to 
the thyroid migration process, the C cells within the fourth pharyngeal pouch 
have localized to a transient embryologic region called the ultimobranchial body 
(UB). From its lateral origin, the UB bodies will migrate medially from either side 
of the neck. By day 70, the TFC and C cells that make up the mature and 
differentiated thyroid gland have now merged anterior to the cricoid cartilage on 
the trachea. The thyroid gland then begins to expand and the TFC, which vastly 
outnumber the interspersed C cells, organized into follicles. The final dispersion if 
C-cells within the thyroid are not uniform as they are concentrated within the 
middle and upper thirds of the lateral lobes of the gland. Functional 
differentiation of the TFC, and ultimately hormone production, is the final step in 
normal organogenesis. The proteins and pathways required for hormone 
synthesis are expressed once the thyroid reaches its final location on the trachea 
[Parlato et al., 2004]. 
Mice models demonstrate that T4 is present shortly after folliculogenesis begins 
and human fetal serum contains both thyroid-stimulating hormone (TSH) and T4 
after 12 weeks. Much of what drivers thyroid morphogenesis, has been 
determined from a combination of studies on inherited disorders of the thyroid 
and mice models which are considered an excellent homolog for human thyroid 
development [Van Vliet, 2003].  
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Figure 1: Overview of thyroid morphogenesis. Panel A: A frontal view of the migration 
paths of the lateral and median thyroid anlagen in relationship with other structures of 
the head and neck [Parlato et al., 2004]. Panel B: Schematic representation of the stages 
of development of the thyroid follicular cells [Van Vliet, 2003]. 
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1.1.2 Genetic component on thyroid development 
 
The molecular basis of thyroid gland development began to be investigated with 
the discovery that the transcription factor Titf1/Nkx2-1, identified as responsible 
for the thyroid-specific expression of Tg and TPO, is expressed not only in 
functioning thyroid cells but also in their precursors [Gillam and Kopp, 2001]. 
Subsequently, the transcription factors Foxe1, Pax8, and Hhex were also found to 
be expressed both in mature thyroid cells and in their precursors [Di Lauro, 
2003]. The expression of these factors in the thyroid anlage, at the very 
beginning of thyroid morphogenesis, immediately suggested that these genes 
might play an important role in the organogenesis of the thyroid gland. These 
factors are also present in other embryonic tissues, but all four are co-expressed 
only in the thyroid anlage [Van Vilet, 2003]. Thus, the small number of cells in the 
primitive pharynx fated to become TFCs already at E24 are univocally 
characterized by the simultaneous expression of Titf1/Nkx2-1, [De Felice and Di 
Lauro, 2007], Foxe1 [Kimura, 2011], Pax8 [Trueba et al., 2005], and Hhex [Lacroix 
et al., 2006]. When the thyroid diverticulum forms and begins its migration, the 
expression of these factors is restricted to the thyroid primordium as they are 
never expressed in the thyroglossal duct [Fagman and Nilsson, 2011]. 
These genes continue to drive thyroid development until the gland has 
completed migration and begins to enlarge. At this stage other genes are 
activated and pathways for hormone synthesis begin to develop. In the 10th and 
11th week it is the serial expression of genes such as Fgfr2 and Tshr that prompts 
the production of thyroglobulin (Tg), thyroid peroxidase (TPO), and the TSH 
receptor (Tshr) [De Felice and Di Lauro, 2007]. By the 12th week the sodium-
iodide symporter (NIS) gene is activated and soon after the NIS is found in 
thyroid cell membranes. This heralds the final step in cellular differentiation as 
thyroid hormone is detected in fetal circulation shortly after NIS expression (12th 
week) (Figure 2). 
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Figure 2: Thyroid development in humans: schematic illustrations. The time of 
development is E (embryonic day post-fertilization).  Red color indicates developing 
thyroid follicular tissue. (a) early marker gene expression in endoderm; (b) primordium 
at ventral midline of the pharynx; (c, d) evagination and re-localization; (e) bifurcation of 
primordium; (f) growth of thyroid follicular cells, surrounded by connective tissue; 
differentiation into many follicles at the same time; (g) differentiation into one first 
follicle; (h) growth of follicles. Blue arrows indicate the onset of early and differentiative 
marker gene expression. Green arrows indicate the onset of thyroid proliferation; 
orange arrows indicate the onset of thyroid function as judged by T4 production 
[Fagman and Nilsson, 2010]. 
 
 
 
1.2 THYROID HORMONE METABOLISM AND ACTION 
 
Thyroid hormone (TH) has long been known to be important for organ function 
and metabolism in adult vertebrates and for embryo development [Brix et al., 
2011]. The most obvious and earliest known abnormalities of human body and 
behavior associated with TH deﬁciency are goiter and cretinism [Nishimaki et al., 
2009; Ilyés, 2011]. In humans, the most important period of TH action 
responsible for cretinism appears to be the so-called postembryonic period, a 
few months before and several months after birth, which is critical for growth 
and maturation of many organs, including the brain [Yassa et al., 2010].  
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As previously reported, during human development, TH begins to explain his role 
very early [Medici et al., 2011]. The thyroid gland is developed within the ﬁrst 12 
weeks of gestation. In vitro organ culture studies of human thyroid tissue suggest 
that fetal TH production begins as early as 10 weeks of gestation, although 
signiﬁcant TH production probably does not occur until 20 weeks or later [De 
Felice and Di Lauro, 2007]. In the fetal plasma, TH levels, especially 3,5,30-
triiodothyronine (T3), remain low until about 4 months prior to birth when 
endogenous synthesis of TH leads to a rapid increase in plasma TH levels. The TH 
levels reach a peak at birth and remain high several months after birth. Thus, it 
may not be surprising that TH deﬁciency during the neonatal period leads to 
irreversible, profound neurological deﬁcit and mental retardation [Hubalewska-
Dydejczyk et al., 2011]. In addition to fetal TH, maternal TH also plays an 
important role in early embryogenesis [Mortimer et al., 2012]. On the other 
hand, excess TH also impairs embryo development, leading to increased 
miscarriages and lower birth weights [Alvarez-Pedrerol et al., 2008]. Although TH 
is clearly important for embryogenesis in humans and other mammals, it has 
been difﬁcult to investigate the underlying mechanisms in mammals. This is in 
part due to the difﬁculty to manipulate the uterus-enclosed mammalian embryos 
and to separate the direct effects of TH on embryos from the indirect maternal 
effects caused by altering TH levels [Bünger et al., 1998]. 
The biological effects of TH are mainly mediated through gene regulation by TH 
receptors (TRs), although non-genomic effects of TH have been well documented 
[Radenne et al., 2008; Lin et al., 2011]. There are two evolutionary-conserved TR 
genes, TRa and TR, in all vertebrate species and both are members of the 
nuclear hormone receptor superfamily [Tarim, 2011]. TRs are capable of 
functioning as monomers, homodimers, and heterodimers with 9-cis-retinoic 
acid receptors (RXRs), which belong to the same superfamily. For genes induced 
by TH, TR-RXR heterodimers bind to TH response elements (TREs) in around the 
promoters of target genes even in the context of chromatin [Jones and Shi, 
2003]. In the absence of TH, TR represses transcription from their promoters; 
when TH is present, TR activates their transcription, accompanied by chromatin 
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disruption [Wang et al., 2009]. There are also genes that are repressed by the 
presence of TH. TR accomplishes gene regulation by recruiting corepressor or 
coactivator complexes to the target promoters, respectively. Many TR-
interacting proteins have been isolated and characterized through in vitro and 
cell culture studies [Ortiga-Carvalho et al., 2005]. Two highly related proteins N-
CoR (nuclear corepressor) and SMRT (silencing mediator of retinoid and thyroid 
hormone receptors) are among the best-studied TR-binding corepressors 
[Astapova et al., 2011]. Both bind to unliganded TR and form large complexes 
containing histone deacetylase 3 (HDAC3), transducin beta-like protein 1 (TBL1), 
TBL1-related protein 1 (TBLR1), and G-protein pathway suppressor 2 (GPS2), 
suggesting that unliganded TR represses transcription in part through 
deacetylation of the local histones at target promoters [Jones et al., 2003]. In the 
presence of TH, TR releases corepressors and recruits coactivators. The known 
TR coactivators include ATP-dependent chromatin-remodeling proteins, histone 
acetyltransferases such as CREB-binding protein (CBP) and p300, and 
TRAP=DRIP=mediator complex that associates with the recruitment and 
activation of RNA polymerase II [Li et al., 1997]. 
 Among the coactivators, the role of the SRC family (SRC1, 2, 3) in gene 
regulation by TR has been studied extensively. SRCs bind to TR in the presence of 
TH and form complexes with other cofactors, including CBP=p300, protein 
arginine methyltransferase 1 (PRMT1), and coactivator-associated arginine 
methyltransferase 1 (CARM1 or PRMT4) [34], suggesting that SRCs activate 
transcription in part through acetylation or methylation of local histones in the 
promoter region (Figure 3) [Jones et al., 2003]. 
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Figure 3: Mechanisms of transcriptional regulation by thyroid hormone (TH) receptor 
(TR). For TH-inducible genes, TR heterodimerized with 9-cis-retinoic acid receptors (RXR) 
constitutively binds the TH response elements (TREs) in their promoters or enhancers. In 
the absence of TH, TR binds corepressor complexes, such as those containing histone 
deacetylase HDAC3 and the highly related protein N-CoR (nuclear corepressor) or SMRT 
(silencing mediator of retinoid and thyroid hormone receptors) to inhibit transcription 
from the promoters through deacetylation of lysine residues of histone H3 and H4 to 
induce a ‘‘closed’’ chromatin state, as suggested by the folding of histone tails (red 
beaded structure) on to the DNA helix because of the charge–charge interaction 
between the positively charged histone tails and negatively charged DNA. The binding by 
TH induces a conformational change in TR, leading to the binding of coactivator 
complexes, such as those containing the related coactivators SRC 1, 2, or 3, which in turn 
binds p300 and PRMT1. SRCs and p300 have histone acetyltransferase (HAT) activity to 
acetylate histones H3 and H4, and PRMT1 can methylate histone H4. Histone acetylation 
is believed to facilitate the formation of an ‘‘open’’ chromatin state, as diagramed by the 
unfolding of histone tails (red beaded structure) away from the DNA helix due to the 
neutralization of the positive charges on the histone tails by acetylation. There are other 
corepressors and coactivators that can participate in this process, including those 
involved in chromatin disruption upon transcriptional activation by TR [Jones et al., 
2003]. 
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1.3 CONGENITAL HYPOTHYROIDISM 
 
Congenital hypothyroidism (CH) is the most common congenital endocrine 
disorder (about one in 3000 newborns). Because the hormone thyroxine (T4), 
produced by the thyroid gland, is essential for brain development, CH represents 
the most common preventable cause of mental retardation [Rastologi et al., 
2010]. Very rarely, CH is due to pituitary or hypothalamic defects resulting in 
‘central’ hypothyroidism [Nebesio et al., 2010], but it is most often due to a 
defect at the level of the thyroid gland itself (‘primary’ hypothyroidism) [Bros et 
al., 2009]. In the following paragraphs are reported the knowing causes of 
primary congenital hypothyroidism.  
 
1.3.1 Thyroid Dysgenesis  
 
Unlike in iodine-deficient areas of the world where endemic cretinism continues 
to be a major health hazard, the majority (85 to 90%) of cases of permanent 
congenital hypothyroidism are due to thyroid dysgenesis [Thorwarth et al., 
2010]. Thyroid dysgenesis may result in the complete absence of thyroid tissue 
(agenesis) or it may be partial (hypoplasia); the latter often is accompanied by a 
failure to descend into the neck (ectopy) [Rastologi et al., 2010]. Females are 
affected twice as often as males. In the United States, thyroid dysgenesis, is less 
frequent among African Americans and more common among Hispanics and 
Asians [Miyai et al., 1984]. Babies with CH have an increased incidence of cardiac 
anomalies, particularly atrial and ventricular septal defects [Devos et al., 1999]. 
An increased prevalence of renal and urinary tract anomalies has also been 
reported recently [Trueba et al., 2005]. 
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Most cases of thyroid dysgenesis are sporadic. Although both genetic and 
environmental factors have been implicated in its etiology, in most cases the 
cause is unknown [Castanet et al., 2010; Büyükgebiz, 2003]. The occasional 
familial occurrence, the higher prevalence of thyroid dysgenesis in babies of 
certain ethnic groups and in female versus male infants as well as the increased 
incidence in babies with Down syndrome all suggest that genetic factors might 
play a role in some patients [LaFranchi, 199; Nebesio and Eugster, 2009]. The 
transcription factors NKX2.1 (TTF1), FOXE1 (TTF2) and PAX8 would appear to be 
obvious candidate genes in view of their important role in thyroid organogenesis 
and in thyroid-specific gene expression [Fagman et al., 2011; Di Palma et al., 
2010]. To date, however, abnormalities in these genes have been found in only a 
small proportion of affected patients, usually in association with other 
developmental abnormalities [Kempers et al., 2009]. For example, the syndrome 
of congenital hypothyroidism associated with unexplained neonatal respiratory 
distress, ataxia, and developmental delay has been found in a number of patients 
with genetic abnormalities of NKX2.1 [Doyle et al., 2004], analogous to the 
findings of abnormal thyroid, lung, pituitary, and forebrain development in mice 
with a targeted disruption of this gene [De Felice et al., 1998; Argumedo et al., 
2011]. In contrast, no germline mutations in NKX2.1 gene were found in a total 
of 76 patients with isolated CH [Montanelli and Tonacchera, 2010]. A similar 
situation has been found with FOXE1 (TTF2), a mutation which has been 
reported in 2 siblings with the combination of thyroid agenesis, cleft palate, spiky 
hair and choanal atresia [Tonacchera et al., 2004]. In a different study, germline 
mutations of PAX8 were found in only 2 of 145 Italian patients with sporadic 
thyroid dysgenesis studied [Di Palma et al., 2010]. In one of these latter patients, 
the thyroid gland was hypoplastic and ectopic while in the other patient the 
thyroid gland was hypoplastic but located in a normal position in the neck 
[Montanelli and Tonacchera, 2010]. Since PAX8 is also involved in renal 
development it will be important to determine whether this gene is related to 
the increased prevalence of renal urinary tract anomalies that has been noted 
recently [Trueba et al., 2005]. It is possible that thyroid dysgenesis is a polygenic 
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disease with variable penetrance depending on the genetic background. 
Alternately, epigenetic modifications, early somatic mutations or stochastic 
developmental events may play a role [Vassart and Dumont, 2005].  
 
1.3.2 Dysormonogenesis 
 
Inborn errors of thyroid hormonogenesis are responsible for most of the 
remaining cases (15%) of neonatal hypothyroidism [Topaloglu, 2006]. A number 
of different defects have been characterized and include: 1) decreased TSH) 
responsiveness, 2) failure to concentrate iodide, 3) defective organification of 
iodide due to an abnormality in the peroxidase enzyme or in the H2O2 
generating system, 4) defective thyroglobulin synthesis or transport, and 5) 
abnormal iodotyrosine deiodinase activity [Kota et al., 2011, Moreno and Visser, 
2007; Turkkahraman et al., 2009]. The association of an organification defect 
with sensorineural deafness is known as Pendred syndrome [Coakley et al., 
1992]. Though usually included in causes of congenital hypothyroidism because it 
is caused by a genetic defect, Pendred syndrome rarely presents in the newborn 
period [Banghová et al., 2008]. Unlike thyroid dysgenesis, a sporadic condition, 
these inborn errors of thyroid hormonogenesis are commonly associated with an 
autosomal recessive form of inheritance, consistent with a single gene 
abnormality [Narumi et al., 2011]. Genetic component involved mutations the 
genes for the TSH receptor (TSHR), the sodium-iodide symporter (NIS), thyroid 
peroxidase (TPO), dual oxidase (DUOX) 2, thyroglobulin (Tg), and iodotyrosine 
deiodinase (DEHAL1) [Grasberger et al., 2011].  All of the inborn errors of thyroid 
hormonogenesis except decreased TSH responsiveness are associated with a 
normally placed (‘eutopic’) thyroid gland that may be increased in size at birth 
and this feature forms the basis for the clinical distinction from thyroid 
dysgenesis [Park and Chatterjee, 2005]. In contrast, most babies with TSH 
resistance have a normal or hypoplastic, eutopic gland that may in some cases 
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mimic an abnormality of thyroid gland development; in rare cases no thyroid 
gland at all is discernible on thyroid imaging, a picture indistinguishable from 
thyroid agenesis. Similar to the variability observed in thyroid gland size in this 
condition, the clinical findings in TSH resistance have varied from subclinical to 
overt hypothyroidism depending on the severity of the functional defect [Persani 
et al., 2011]. Some of these patients have been found to have a loss of function 
mutation of the TSH receptor, analogous to the hyt/hyt mouse [Sprenkle et al., 
2001. In a few affected infants, a discrepancy between presumed ‘athyreosis’ on 
thyroid scintigraphy and the detection of either a ‘normal’ serum thyroglobulin 
concentration or glandular tissue on ultrasound examination has been noted, a 
feature that may be helpful diagnostically [Alberti et al., 2002].  
  
1.3.3 Incidences of congenital hypothyroidism 
 
Prior to the onset of newborn screening programs, the incidence of congenital 
hypothyroidism, as diagnosed after clinical manifestations, was in the range of 
1;7,000 to 1:10,000 [Dassault et al., 1975]. With the advent of screening of 
newborn populations, the incidence was initially reported to be in the range of 
1:3,000 to 1:4,000 [Harris and Pass, 2007; Olney et al., 2010].  
With more experience from state, regional, and national screening programs, it 
has become apparent that the incidence varies by geographic location. A report 
from the French newborn screening program summarizing a 20 year period 
found the incidence of permanent hypothyroidism to be 1:10,000 [Farriaux and 
Dhondt JL, 1988], whereas a report from the Greek Cypriot population over an 
11 year period found the incidence in newborns to be 1:800 [Skordis et al., 
2005]. A recent report showed that the incidence in the United States increased 
from 1:4,094 in 1987 to 1:2,372 in 2002 [Shapira et al., 2010]. 
Even in Italy, The Italian National Population-Based Registry of Infants with CH 
(INRCH) was established in Italy in 1987 shown that the incidence of CH is about 
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1:2400 live births, an incidence slightly higher than that observed in other 
countries where iodine prophylaxis is carried out [Corbetta et al., 2009]. 
 
The reasons for the increased incidence are not clear, but one possible 
explanation may be a change in testing strategy. With increased sensitivity and 
accuracy of TSH methods, Italian and other programs around the world have 
switched from a primary T4-follow- up TSH approach to a primary TSH test. If the 
TSH cutoff is lowered, more infants with milder congenital hypothyroidism will 
be detected [Pass and Neto, 2009; Lafranchi, 2010].  
 
Interestingly, there is some variation in the incidence among: 
  
 Different racial and ethnic groups:  several U.S. programs have reported a 
higher incidence in the Asian, Native American, and Hispanic populations 
and lower in the American Black population as compared to the White 
population. A summary of the New York State program during the years 
2000 to 2003 showed some interesting demographic variations in the 
incidence of congenital hypothyroidism. As compared to the overall 
incidence of congenital hypothyroidism, the incidence was somewhat 
lower in Whites (1:1815) and Blacks (1:1902), somewhat higher in 
Hispanics (1:1559), and highest in the Asian population (1:1016) [Shapira 
et al., 2010].  
 
 Multiple deliveries: several reports indicates that the incidence of CH is 
nearly double in twin births as compared to singletons, and even higher 
with multiple births [Derom et al., 1995; Olivieri et al., 2007].On this 
regard, in Italy, the INRICH data have also shown a high frequency of 
twins in the CH population with a proportion 3-fold higher in the CH 
population (3.5%) than in the Italian general population (1.1%) [Olivieri et 
al., 2007].It was found 3-fold higher in multiple (10.1 per 10,000 live 
births) than in single deliveries (3.2 per 10,000 live births) with a relative 
20 
 
risk of CH occurrence in twin deliveries of 3.1 (95% CI, 2.5–3.9) [Corbetta 
et al., 2009]. Moreover, the analysis of re-evaluated infants with high 
suspicion of transient hypothyroidism recorded in the INRICH has shown 
a twin prevalence of 1.9% among infants who were affected by 
permanent CH and 13.2% in those who resulted affected by transient CH. 
Taken together these findings have demonstrated an increased risk for 
both permanent and transient CH in multiple than in single deliveries. 
This increased CH risk in multiple pregnancies has important implications 
in terms of public health given the high number of induced pregnancies, 
in Italy as well as in other Western countries, because of the increasing 
use of techniques of assisted reproduction and drugs inducing ovulation 
[Umstad and Gronow, 2003; Olivieri et al., 2010].  
 
 Prematurity and fetal growth:  some reports indicate that children born 
prematurely, independently from their birth weight or length, frequently 
present with disturbances of the hypothalamus-pituitary-thyroid axis 
later in life with a incidence 3-fold higher than term infants [Radetti et al., 
2007; Srinivasan et al., 2011; Linn et al., 2010]. Instead, other work 
indicated that intrauterine growth restriction is associated with some 
endocrine disturbances later on life [Dahlgren et al., 1998; Cianfarani et 
al., 2003]. Premature babies born small for gestational age (SGA) have an 
incidence 12% higher than premature children born acceptable for 
gestational age (AGA) [Radetti et al., 2004]. What causes the alteration in 
the hypothalamus-pituitary-thyroid-axis is still unknown. Iodine 
deficiency, adverse maternal conditions such as diabetes and thyroid 
autoantibodies during pregnancy seems to be play an important role 
[Simpser et al., 2010] 
 
 Congenital malformations and CH: anomalies of heart, nervous system, 
eyes (representing precocious structures in the developing embryo) and 
multiple congenital malformations are significantly associated to CH 
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[Reddy et al., 2010]. Babies with CH shown a 3-4 fold higher incidence of 
cardiac disease [Passeri et al., 2011]. These findings have strongly 
suggested a very early impairment in the first stages of embryo 
development with a consequent involvement of different organs and 
structures [Kreisner et al., 2005]. 
 
 
It’s clear that the etiophatogenesis of CH is influenced by several factors. It has 
been demonstrated that CH is a multigenic [Amendola et al., 2005; Amendola et 
al., 2010] and multifactorial disease [Vassart and Dumont, 2005]. However, the 
occurrence of mutations in genes known to be involved in the development of 
the disease has been observed only in a small proportion of the CH patients 
[Lafranchi, 1999]. These considerations imply that the etiology of CH is still 
largely unknown and that further efforts to identify new genetic markers and 
modifiable environmental risk factors are needed to allow an efficient primary 
prevention of the disease. The multifactorial origin of CH was also supported by 
results obtained in the above mentioned study on CH twins recorded in the 
INRICH [Corbetta et al., 2009; Olivieri et al., 2007]. These findings strongly 
suggested the occurrence of non-inheritable postzygotic events in the etiology of 
CH and that environmental risk factors may act as a trigger on a susceptible 
genetic background in the etiology of the disease [Gilbert et al., 2011].  
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INTRODUCTION-CHAPTER II 
2. EPIGENETIC MECHANISMS 
2.1 A BRIEF OVERVIEW 
 
The term epigenetics was originally coined in the 1940s to describe the interplay 
of genes and environmental factors or stimuli that produce a resultant 
phenotype, long before the mechanisms underscoring such events were known 
[Waddington, 1942]. While an organism’s cells all hold the same genetic code, it 
is axiomatic that this information is not expressed uniformly across all cell types. 
Instead, the modification of additional layers of information residing “on top of” 
the bare genomic sequence helps contribute to cellular phenotypic variance [Wu 
and Morris, 2001].  
It is important to note that epigenetic modification is a normal and ubiquitous 
process. Initially, certain divergent genes become epigenetically suppressed 
during embryonic differentiation [Christophersen and Helin, 2010]. This “locks 
in” the cell’s basic expression profile and contributes to the resultant 
morphological and functional diversity among cell phenotypes. Furthermore, 
once established, these epigenetic changes can be stable and have the ability to 
persist through multiple cellular divisions of the differentiated line; in other 
words, they are heritable. In some circumstances, epigenetic marks may even be 
persistent across generations, passed meiotically from parent to offspring [De 
Carvalho et al., 2010].  
Today, there is indeed growing evidence that external factors such as diet, for 
example, have the ability to alter phenotypic outcomes via changes in recently-
discovered epigenetic machinery [Sebert et al., 2011; Slattery et al., 2010]. 
Interestingly, some reports suggested that such plasticity under the jurisdiction 
of environmental cues could constitute an organism’s ability to deliberately 
23 
 
integrate environmental information into its genetic function in effect, a new 
kind of Lamarckism [Kanno et al., 2011; Handel et al., 2010]. In any case, 
epigenetic processes allow the cell to enhance and augment the information 
residing in its DNA and to add nuance to the cell’s control over gene expression. 
For example, epigenetic mechanisms are responsible for the dosage 
compensation phenomena of random X chromosome inactivation and gene 
imprinting [Tarry-Adkins JL and Ozanne, 2011]. The nature of these processes is 
discussed below. 
 
2.2 EPIGENETIC COMPONENTS 
 
At a molecular level, epigenetics involves two main constituents, these being 
histone modification and DNA methylation, although it is increasingly evident 
that non-coding RNAs are implicated in epigenetic maintenance [Golbabapour et 
al., 2011]. Collectively, these mechanisms facilitate the expression or silencing of 
targeted genes that ultimately culminate in the desired cell state, referred to as 
the epigenome [Dupont et al., 2009]. This section will briefly introduce histone 
modification and non-coding RNA, before a more thorough review of DNA 
methylation in section 2.3. 
2.2.1 Histones modifications 
 
The histone family (H2A, H2B, H3 and H4) are highly conserved proteins that, 
when arranged in an octamer, permit 146 bp lengths of genomic DNA to wind 
around them to form a nucleosome. Millions of nucleosomes together with other 
scaffold proteins, collectively referred to as chromatin, allow for the efficient 
packing of DNA into the nucleus [Zweidler, 1984]. The degree to which localized 
sectors of DNA are packaged also dictates how readily accessible the underlying 
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genetic information is to transcription machinery responsible for gene 
expression. Generally, condensed chromatin, or heterochromatin, restricts 
access to DNA sequence and thus represses gene expression, whereas 
euchromatin is in an open conformation that allows binding of transcription 
factors and the RNA polymerase complex [Sierra et al., 1992]. Several covalent 
modifications of histone N-terminal tails exist which are thought to control the 
extent of chromatin packing as well as to recruit and regulate attachment of 
other DNA binding proteins capable of initiating or suppressing transcription. 
Presently, around thirty acetylation, methylation, phosphorylation and 
ubiquitination additions are documented, which are facilitated by multiple 
corresponding acetylases and transferases [Garcia et al., 2008]. Consequently, 
deciphering this regulation is quite complex and can be seemingly contradictory. 
For example, methylation of histone H3-Lys4 leads to a open chromatin structure 
[Hake et al., 2006] whereas methylation of Lys9 of the same histone invokes 
chromatin condensation [Zhao et al., 2005]. Such residues can be mono-, di- or 
tri-methylated, further complicating the understanding of such events [Li et al., 
2007]. Certainly, the picture describing histone modification and control is far 
from complete. The exact nature of proteins that bind modified histone residues 
are still being elucidated. Even the mechanism whereby a histone’s modification 
state is preserved across mitosis is unconfirmed, although division of the 
octamer in a semi-conservative manner analogous to DNA replication is a 
possibility [Hajkova et al., 2008]. 
 
2.2.2 MicroRNAs 
 
The existence of non-coding microRNAs (miRNAs) as epigenetic regulators is a 
recent discovery. Non-coding RNAs participate in regulation of gene expression 
at all stages, including transcription modulation, primary transcript processing 
and mature mRNA stability, and translation repression [Bartel, 2004]. Notably, 
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miRNAs have also been implicated in modification of chromatin and associated 
processes like imprinting. For example, H3-Lys9 methylation in both bacteria and 
mice has been demonstrated to be dependent upon RNA interference (RNAi) 
mechanisms [Cowell et al., 2002]. Double stranded RNAs (dsRNAs), transcribed 
from heterochromatic regions, are processed into small interfering RNAs 
(siRNAs) and integrated into the RNA-induced transcriptional silencing complex 
(RITS). This complex directs the histone methyltransferase to further methylate 
local H3-Lys9 residues, several kilobases around the RNA-targeted site [Bernstein 
et al., 2007]. Additionally, non-coding RNA can assist genomic DNA methylation, 
a process that also contributes to heterochromatin formation. RNA-directed DNA 
methylation (RdDM) functions similarly to the aforementioned procedure, but 
processed dsRNAs are smaller (21-24 nucleotides) and instead recruit DNA 
methyltransferases to the promoter region homologous to the dsRNA [Bartel, 
2004]. Owing to the fact that only a fraction of non-coding RNAs have been 
characterised, considerable further investigation is required to determine the 
extent to which noncoding RNAs control epigenetic events. 
In the following paragraphs, we will focus on the DNA methylation, which is the 
main topic of my PhD thesis. 
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2.3 THE DNA METHYLATION  
 
2.3.1 Introduction of DNA methylation 
 
DNA methylation is a biochemical process that is important for normal 
development in higher organisms. It involves the addition of a methyl group to 
the 5 position of the cytosine pyrimidine ring or the number 6 nitrogen of the 
adenine purine ring (Figure 4). This modification can be inherited through cell 
division [Bird, 2002].  
DNA methylation stably alters the gene expression pattern in cells such that cells 
can "remember where they have been" or decrease gene expression [Reik et al., 
2009]. DNA methylation is typically removed during zygote formation and re-
established through successive cell divisions during development. However, the 
latest research shows that hydroxylation of methyl group occurs rather than 
complete removal of methyl groups in zygote [Surani, 2001]. 
However, these moieties are still able to be added or removed independently of 
genetic duplication [Santos et al., 2002]. DNA methylation also contributes to the 
condensation of chromatin and thus gene suppression. Similarly to the 
mechanisms by which histone modifications are thought to induce changes in 
chromatin, the modification of cytosines aids the binding of a family of methyl 
binding domain proteins (MBDs) that facilitate chromatin modification or act as 
linkers to recruit DNA methyltransferases to further methylate adjacent cytosine 
[Fulka et al., 2004; Paulsen et al., 2008]. Alternatively, the presence of a methyl 
group can interfere with trans-factor binding, thus altering the ability of the 
underlying genetic material to be expressed. This process is depicted in Figure 5. 
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Figure 4: DNA methylation. A covalent addiction of methyl group on carbon in position 
5’ of cytosine forms a 5Met-Cytosine.   
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Figure 5: General mechanism of transcriptional silencing involving DNA methylation. 
Panel A: Active gene promoters are characterized by an open chromatin structure, 
facilitated by acetylated histones which permit low nucleosome occupancy (acetyl 
groups denoted by cyan spheres). Cytosine methylation of the DNA locus is performed 
by DNA methyltransferases (gold cylinder). Panel B: Addition of methyl groups attracts 
Trans-acting factors with methyl binding domains (MBDs, denoted as green ovals), a 
family comprised of MeCP2, MBD1, MBD2 and MBD4. These proteins recruit additional 
factors to interfere with transcriptional machinery (co-repressors shown as red cylinders 
in Panel C) and condense chromatin by altering histone tags (histone deacetylases and 
methylated histone tags represented by yellow cylinders and red cubes, respectively), 
which also occludes DNA sequence from the polymerase complex. Panel C: As a result, 
transcription is repressed. Note, the temporal sequence of these events varies and in 
some instances, histone modification precedes DNA methylation [Fulka et al., 2004]. 
 
 
2.3.2 5′-Methylcytosine and the CpG dinucleotide 
 
A methyl moiety covalently bonded to the 5′ carbon of the pyrimidine ring of 
cytosine is the predominant form of DNA methylation. In mammals, cytosine 
methylation generally only occurs when that residue is adjacent to a 3′ 
guanosine, termed a CpG dinucleotide [Bird, 2002]. The “p” represents the 
phosphodiester bond between nucleotides. Significant methylation of other 
cytosine-containing di- and trinucleotides does exist however. For example, 
plants exhibit more complicated CpNpG and CpNpN patterns, where N is any 
nucleotide [Zilberman et al., 2007]. Another example is during fetal 
development, where non CpG methylation is witnessed [Lister et al., 2009].  
In essence, each CpG dinucleotide pair is a palindrome and the methyl moiety 
shares this reciprocity with cytosines of both DNA strands being methylated. The 
methyl groups of complimentary CpGs both protrude into the major groove of 
the helix (see Figure 6, panel A). As DNA is replicated semi-conservatively, the 
newly synthesized daughter strand at S phase is devoid of cytosine methylation; 
while adenosine, cytosine, guanine and thymine are present in the cell as free 
29 
 
nucleotides, 5′-methylcytosine only exists as a modification of cytosine once the 
latter has been integrated into the DNA molecule. Therefore, following 
replication, hemi-methylated CpGs are detected and the remaining dinucleotide 
is enzymatically methylated [Jeltsch, 2006]. This method allows faithful 
epigenetic transmission from parent to daughter cell. The process is catalyzed by 
DNA methyltransferases (DNMTs). 
The methyltransferases are coded by three genes, DNMT1, DNMT3A and 
DNMT3B, all of which contain several conserved motifs [Van Emburgh and 
Robertson, 2008]. Interestingly, these motifs are present across all studied 
prokaryotes and eukaryotes [Posfai et al., 1989).]. Multiple splice variants of 
each gene’s transcripts exist in humans. Some isoforms only perform key 
methylation events during embryogenesis, or are sex specific, while DNMT1, the 
prime “maintenance” methyltransferase, is responsible for the routine re-
methylation of the bulk of DNA following replication [Van Emburgh and 
Robertson, 2008].  
However, in addition to primarily recognising hemi-methylated DNA, DNMT1 can 
also conduct de novo methylation [Pradhan et al., 1999]. Conversely, DNMT3 
families are also primarily de novo methyltransferases, but may contribute to 
maintenance methylation [Liang et al., 2002]. DNMT2, originally presumed to act 
exclusively on DNA, has recently been re-categorised as a RNA methylase [Goll et 
al., 2006]. 
The catalytic mechanism by which DNMTs operate is worth mentioning. 
Following substrate recognition, one strand of the DNA is flipped out of the helix 
by the enzyme to expose the acceptor carbon of the unmethylated cytosine. A 
methyl moiety is then transferred from S-adenosylmethionine to the cytosine 
[Cheng and Roberts, 2001; Klimasauskas et al., 1994]. Although only established 
in bacteria, this mechanism is presumed to occur in mammals due to the very 
close sequence homology between proand eukaryotes (see Figure 6, panel B). 
Less is known about the process of methylated cytosine removal. Rapid and large 
scale demethylation is known to occur early during embryonic development, and 
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adult somatic tissues can display a gradual loss of methylation as part of 
senescence and cancer [Issa, 2003; Maegawa et al., 2010].  
This loss of methylation is generally believed to be a passive event, perhaps as a 
result of a breakdown in DNMT-facilitated methylation over multiple cell 
divisions. However, active demethylation mechanisms may exist outside of fetal 
development. The nuclear protein Gadd45a in conjunction with a DNA repair 
endonuclease XPG, leaves damaged CpGs unmarked after repair, which could be 
an attractive mechanism to explain age-related hypomethylation [Barreto et al., 
2007]. There is also accumulating evidence that DNA methylation is dynamic in 
the brain and involved in memory formation [Levenson et al., 2006; Miller and 
Sweatt, 2007], and recent work in plants has discovered multiple DNA 
glycosylases capable of actively performing demethylation via excision ′ of 5 - 
methylcytosine [Agius et al., 2006; Morales-Ruiz et al., 2006]. It is presently 
unclear if this process extends to humans. 
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Figure 6: Attributes of 5′-methylcytosine. Panel A: Spatial representation of methyl 
groups of a CpG dinucleotide pair within the DNA double helix. Methyl moieties 
protrude into the major groove, which suggests their steric interaction with 
methylbinding proteins or transcription factors. Methyl groups are depicted in red. 
Panel B: Cartoon rendering of the 3-dimensional structure of the Haemophilus 
parahaemolyticus DNMT-DNA complex (PDB ID: 1MHT). The enzyme (green) “flips” one 
strand of the DNA (light blue) outwards to expose the unmethylated cytosine residue. 
The methyl moiety (magenta) is then transferred from S-adenosylmethionine to the 5′ 
carbon of cytosine. As there is a very high degree of conservation between bacterial and 
higher eukaryote DNA methyltransferases, this mechanism is also assumed to occur in 
mammals. Images in panels A and B rendered using PyMol version 0.94. Panel C: 
Chemical structures of cytosine, methylcytosine and thymine, highlighting the 
propensity of methylcytosine to deaminate to thymine. The R-group denotes the 
deoxyribose common to all three species [Laird, 1999] 
 
 
2.3.3 Genomic distribution of 5′-methylcytosine 
 
Under conditions of local strand separation, genomic cytosine is prone to 
spontaneous deamination, becoming uracil [Fryxell and Moon, 2005]. 
Fortuitously, the cell has the ability to detect, excise and replace uracil in DNA 
with uracil glycosylase [Lindahl et al., 1997]. However, if the cytosine is 
methylated, the end product of deamination is thymine (see Figure 1.6, panel C), 
a legitimate base which is invisible to the aforementioned corrective machinery. 
Consequently, over time, methylated cytosines have transmogrified to thymine 
residues and CpGs are statistically underrepresented throughout the human 
genome [Lander et al., 2001]. 
Correspondingly, around 1% of nucleotides in adult mammalian genomes are 5′-
methylcytosine (and, as it follows, approximately 4.5% of cytosines). In a given 
human somatic cell, this equates to around 30 million CpG dinucleotides 
[Costello and Brena, 2008]. The distribution of cytosine methylation throughout 
the genome is far from even however, with the bulk of methylation occurring in 
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repetitive elements including transposons and satellite sequences (see Table 
1.1). Approximately 75-80% of CpGs are methylated [Dahl and Guldberg, 2003]. 
Clusters of unmethylated CpGs exist, however, usually within gene promoter 
CpG islands. CpG islands were originally defined as a region with at least 200 bp 
and with a GC percentage that is greater than 50% and with an 
observed/expected CpG ratio that is greater than 0.6 [Gardiner-Garden and 
Frommer, 1987]. More stringency has since been added to this definition to 
exclude much of the CpG content of repetitive elements while retaining islands 
associated with gene regulation [Takai and Jones, 2002]. The revised 
classification specifies that CpG islands are deemed to possess greater than 60% 
GC content and be between 0.5 – 2 kb in length. This is often relaxed in 
circumstances such as algorithmic genome searches [Yamada et al., 2004].  
Ultimately, the CpG sites on the genome can be divided into two broad 
categories: within gene promoters and are called CpG islands or within non-
coding DNA (such as repetitive sequences) and are called non-CpG islands sites 
(see figure 7). The main difference of this CpG sites resides in the physiological 
state of methylation and into the mechanism of inhibition of gene expression. As 
described above, CpG island sites are usually hypomethylated and the covalent 
addition of methyl groups directly prevents the activities of the transcriptional 
machinery complex. On the contrary, non-CpG island sites are normally 
hypermethylated and the gene silencing occurs in an indirect way, through the 
recruitment of protein complex of chromatin condensation [Shen et al., 2007]. 
The details of the mechanisms of gene regulation are described in the following 
paragraph. 
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Table 1: Distribution of CpG dinucleotides in the human genome [Rollins, 2006] 
 
 
 
 
 
Figure 7: Distribution of CpG sites into the genome. CpG islands are located into gene 
promoters and are usually hypomethylated. Non-CpG island sites localize into non-
coding regions such as the body of gene (introns) and DNA repeats (LINE, Alu repeats) 
[Shen et al., 2007].   
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2.3.4 CpG sites help determine gene expression state 
 
The presence of CpG islands around certain gene promoters and first exons, 
particularly of house-keeping genes, suggests a role in regulation of gene 
expression. Indeed, the great majority of CpG islands in these regions appear to 
confer a stable open chromatin conformation and permit ubiquitous expression 
[Weber et al., 2007]. Conversely, many tissue-specific genes lack CpG islands 
which may allow them to be shut down more easily upon differentiation. Such 
genes typically contain a TATA box for a precisely mapped transcription start site 
and specific transcription factor binding, whereas gene promoters containing 
CpG islands can have multiple transcription start sites and are frequently devoid 
of TATA elements [Carninci et al., 2006]. Other factors relating to 5′ CpG islands 
also contribute to the ultimate expression state of a gene, however. These 
include the nature of other various regulatory motifs within the island that 
facilitate transcription factor binding, overall sequence composition of the CpG 
island and the level of GC content, which can affect the amount of “twist” in the 
DNA helix and thereby alter the accessibility of associated proteins [Bock et al., 
2006]. Incidentally, the methylation status of CpG islands further downstream, 
outside the transcription start site, generally have little bearing on transcription 
and do not interfere with elongation [Larsen et al., 1993].  
Adding complexity, there is considerable crosstalk between CpG island 
methylation state, histones, trans-acting factors and non-coding RNA. DNA 
methyltransferases and histone methyltransferases (HMTs) often interact 
directly to methylate CpGs and alter histone conformation of both genes and 
satellite repeat sequences [Lehnertz et al., 2003; Li et al., 2006].  
It is important to note too that unmethylated CpG islands are generally, but not 
always an attribute of positive gene expression. Some strongly unmethylated 
islands can be devoid of expression [Weber et al., 2007] and conversely, active 
histone marks have been shown to override methylated CpGs and force 
transcription [Brinkman et al., 2007]. Additionally, it is not clear if there is a 
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specific temporal sequence of histone modification and DNA methylation that 
culminates in the changed chromatin state [Sims et al., 2008]. While the 
subtleties of CpG island control may not have been completely elucidated, it is 
clear they play an important part in epigenetic gene regulation. 
 
2.4 ROLES OF DNA METHYLATION 
 
Due to its ability to suppress expression, DNA methylation is utilized by the cell 
to affect a number of disparate functions that require such repression the 
sequential switching off of tissue-specific genes during development, 
accountancy of various dosage imbalances, or the suppression of parasitic 
elements. Furthermore, the replication of methylated CpG marks across cell 
divisions allows DNA methylation to act as a faithful epigenetic inheritance 
mechanism. 
2.4.1 Transposon suppression-DNA methylation as a genetic 
defense 
 
As shown in Table 1, around half of all CpGs reside in repetitive sequences and 
such sequences constitute a similar proportion of the human genome. The 
nature of these elements is diverse, including tandem repeats located around 
centromeres and telomeres and numerous classes of transposable elements. 
Many of the latter are inactive due to deletions or mutations, but elements such 
as complete LINE transposons, of which there are almost 100, or LTR 
retrotransposons (endogenous retroviruses, occupying approximately 10% of the 
genome) have the potential to become active and invade functional genomic 
regions [Brouha et al., 2003; Slotkin and Martienssen, 2007]. Doing so can cause 
genomic recombination or chromosome breaks, or disrupt enhancers, 
36 
 
promoters, polyadenylation and splicing of adjacent genes [Girard and Freeling, 
1999].  
Not surprisingly, these elements are suppressed by the cell, being heavily 
methylated and consequently quarantined by heterochromatin. Flagging of these 
sequences for methylation is presumed to occur by sequence recognition, but 
also by virtue of their high copy number, experiments increasing the amount of 
introduced transgene sequence have been shown to increase its methylation by 
the host, for example [Garrick et al., 1998].  
DNA methylation of these “parasitic” elements occurs across animals, plants and 
fungi. As such, it has been proposed that DNA methylation originally evolved as a 
host defense mechanism to protect against foreign DNA integration and that 
utilization of DNA methylation for host gene regulation was a later adoption 
[Yoder et al., 1997]. 
 
2.4.2 DNA methylation and development 
 
Mammalian development is characterized by bimodal DNA methylation 
reprogramming that occurs initially during germ cell development and then 
during preimplantation (Figure 8) [Kafri et al., 1992]. Primordial germ cells (PGCs) 
enter the developing germinal ridge and begin differentiation and expansion. At 
this time, the highly methylated PGCs undergo rapid genome-wide 
demethylation such that by day 12.5 most of the methylation is lost [Sandovici et 
al., 2008]. This reprogramming phase coincides with the erasure and resetting of 
parent of-origin speciﬁc marks that include DNA methylation of imprinted DMRs 
associated with allele-speciﬁc gene expression [Shafa et al., 2010]. The exact 
timing of de novo methylation has not been ﬁrmly established but is initiated in 
males at 14.5 dpc (days post-coitum) and thereafter in females such that the 
mature gametes of both sexes will eventually become highly methylated. The 
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second phase of methylation reprogramming occurs between fertilization and 
formation of the blastocyst. On fertilization a rapid paternal-speciﬁc asymmetric 
loss of methylation is observed [Shiota, 2004]. This process takes place in the 
absence of transcription or DNA replication and is termed active demethylation. 
Thereafter, there is a step-wise decline in methylation until the morula stage. 
This decline occurs as a result of the absence of the primary DNA methyl 
transferase, Dnmt1, during DNA replication [Klug et al., 2010]. Thus, the newly 
replicated strand fails to become methylated and the level of methyl cytosine per 
nucleus declines. This replication-dependent loss of DNA methylation is referred 
to as passive demethylation. The initiation of the de novo methylation occurs 
after the ﬁfth cell cycle and coincides with the time of the ﬁrst differentiative 
event. The establishment of the ﬁrst two cell lineages results in yet another 
signiﬁcant asymmetry. The inner cell mass (ICM), which gives rise to all the 
tissues of the adult, becomes hypermethylated, while the trophectoderm (TE), 
that forms most of the structure of the placenta, is undermethylated [Jones and 
Laird, 1999]. This differential is maintained and reﬂected in highly methylated 
somatic tissues and the distinctively hypomethylated extra-embryonic tissues of 
the placenta. Among the somatic tissues that derive from the ICM are the highly 
methylated PGCs which arise, day 7 in the extraembryonic mesoderm of the 
developing embryo. Their migration via the allantois to the developing germinal 
ridges, where they will eventually differentiate into mature gametes, completes 
the cycle of epigenetic reprogramming [Sarge and Park-Sarge, 2005]. 
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Figure 8: representation of epigenetic reprogramming in mammalian development. 
 
 
 
 
 
2.4.3 X chromosome inactivation 
 
Another intriguing process in mammalian embryo development is X inactivation. 
One of the two X chromosomes in females becomes transcriptionally inactive (Xi) 
to yield a single X chromosome gene dose comparable to a male XY embryo 
[Boumil and Lee, 2001]. This process is mediated in part by CpG methylation. 
Specifically, partial inactivation of the paternal X chromosome is observed from 
the two-cell to the early blastocyst stage. This is retained in the non-embryo-
forming cells, which develop into the placenta, but reactivated at the late 
blastocyst stage in the inner cell mass which later forms the embryo [Sengupta et 
al., 2008]. One of the two active X chromosomes is then randomly inactivated in 
these cells so that all future embryonic development is dosage-compensated. 
The initial paternal X inactivation is carried over from that chromosome’s 
silencing during spermatogenesis. During oogenesis, the maternal X is marked 
with an imprint to make it resistant to inactivation in extra-embryonic tissues 
after fertilization [Tada et al., 2000]. Embryonic X inactivation occurs when the 
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non-translated RNA Xist, transcribed from the chosen Xi chromosome coats itself 
over the entire chromosome [Clemson et al., 1996]. This induces an ordered 
progression of histone modification, DNA methylation and heterochromatin 
formation, transcriptionally silencing the chromosome [Kay et al., 1993; Wutz 
and Jaenisch, 2000]. Once established, heavy DNA methylation maintains gene 
promoter silencing and a heterochromatic state over subsequent cell divisions. A 
small, variable fraction of genes escape this suppression, however, which may 
contribute to expression heterogeneity among females [Carrel and Willard, 
2005]. DNA methylation may also be a determinant of Xist suppression prior to X 
chromosome inactivation, with DNMT3a recruited to methylate regions flanking 
the gene, preventing transcription [Panning, 2008]. 
 
2.4.4 Imprinting 
 
The phenomenon of imprinting relates to around 50 known genes in the human 
genome [Morison et al., 2005]. Imprinted genes are characterized by gene 
methylation (or more specifically, regulatory element patterns) that are specific 
to each of the parental alleles. Consequently, transcription occurs in a 
monoallelic, parent-of-origin-specific fashion, i.e. only from the paternally-
inherited allele or the maternally-inherited allele [Ferguson-Smith et al., 1993]. 
Imprints are set up during the formation of parental gametes and escape the 
resetting of methylation marks in the morula [Reik et al., 2001].  
In mammals, imprinting is predominantly associated with genes involved in the 
regulation of fetal growth and development and postnatal behaviour [Reik and 
Dean, 2001]. Interestingly, many paternally expressed genes promote prenatal 
growth whereas many maternally expressed genes limit it. It has been postulated 
that this pattern has arisen evolutionarily to balance paternal and maternal 
resource allocation and gene fitness enhanced fetal growth gives a selection 
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advantage to help continue the paternal DNA lineage, but the associated 
increased nutritional cost may compromise the total reproductive success of the 
mother, hence the maternal desire to limit fetal growth [Haig and Graham, 
1991]. It should be noted that not all imprinted genes fit this model, however. 
Probably the best-characterised example of imprinting is that of the paternally-
expressed insulin-like growth factor 2 gene (IGF2), which codes for a hormone 
that promotes growth during gestation, and the reciprocally regulated, 
maternally expressed H19 gene, which transcribes a putative tumour suppressor 
non-coding RNA [Barlow et al., 1991; Rachmilewitz et al., 1992; Zhang and Tycko, 
1992]. Both genes are co-localized with numerous other imprinted genes at 
11p15.5 and are separated by a differentially-methylated, imprinting control 
region, DMR1. Lack of DMR methylation on the maternal allele allows for 
expression of the downstream H19 gene, but also facilitates the binding of 
methylation-sensitive insulator elements (CTCF) to motifs in the DMR which 
block 3′ enhancers vital for IGF2 expression. Conversely, paternal DMR 
methylation suppresses H19 expression and prevents CTCF insulators from 
occluding IGF2 enhancers [Du et al., 2003; Takai et al., 2001; Webber et al., 
1998]. Errors in methylation of this region, such as loss of imprinting or 
hypermethylation of the maternal H19 DMR, result in under or over expression 
of IGF2 respectively. Overgrowth conditions like Beckwith-Wiedemann Syndrome 
can often be attributed to this dysregulation, which also have a predisposition 
towards malignancies such as Wilms tumour [Cui et al., 2001; Weksberg et al., 
2003]. In fact, as described in chapter III, numerous perturbations in the wider 
methylome can have multiple disease outcomes. 
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INTRODUCTION-CHAPTER III 
3. DNA METHYLATION AND HUMAN DISEASES 
3.1 EPIGENETIC DYSREGULATION IN HUMAN DISEASES 
 
The role of epigenetic dysregulation in human disease has been reviewed 
extensively. We therefore summarize only the most salient points here. 
3.1.1 DNA Methylation and cancer 
 
Cancer has been traditionally regarded as a cumulative series of genetic 
alterations resulting in deregulated cell growth. In the early 1980s, 
hypomethylation of RAS oncogenes in malignant tissue were reported, indicating 
epigenetic factors may contribute to tumorigenesis [Feinberg and Vogelstein, 
1983]. Altered DNA methylation is now regarded as one of the most common 
molecular changes in human neoplasm development [Baylin et al., 1998; Jones 
and Baylin, 2002]. Interestingly, aberrant methylation coexists as a non-specific 
global hypomethylation of the genome and defined regions of hypermethylation. 
A decrease in global methylation occurs early in tumorigenesis, and its extent 
mirrors the progression of the disease [Hernandez-Blazquez et al., 2000; Watts et 
al., 2008].  Hypomethylation can up-regulate proto-oncogenes as well as alter 
heterochromatin or satellite DNA. The latter perturbations can activate latent 
transposons and induce chromosomal rearrangement, instability and poor 
chromosomal segregation during mitosis [Bouzinba-Segard et al., 2006; Howard 
et al., 2008; Wong et al., 2006]. Cells with this hypomethylated attribute have 
been described as having a “mutator phenotype”, as the propensity for 
chromosomal deletion or recombination can elevate mutation rates in other 
genes [Frigola et al., 2006; Novak et al., 2006].  
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For the most part hypermethylation is confined to discrete promoter CpG islands 
with neighbouring genes being unaffected, however entire chromosomal bands 
undergoing methylation-mediated suppression have been reported in colorectal 
and breast cancer cases [Chen et al., 1998].  Hypermethylation of gene 
promoters causes their suppression and most aspects of tumorigenesis are 
affected by such aberrant methylation. Disruption of genes involved in cell cycle 
[Ferguson et al., 2000; Greger et al., 1989; Herman et al., 1994; Liang et al., 2000; 
Merlo et al., 1995; Sakai et al., 1991; Stirzaker et al., 1997], DNA repair 
mechanisms [Esteller et al., 2001; Esteller et al., 2000; Hegi et al., 2005; Herman  
al., 1998] which can induce chromosomal instability [Ahuja et al., 1997], and 
apoptosis [Conway et al., 2000; Katzenellenbogen et al., 1999; Teitz et al., 2000] 
are all affected. Exactly how aberrant methylation manifests during 
tumorigenesis and what drivers are responsible is an area of active research. 
Numerous environmental effectors, particularly diet, have been implicated in 
both cancer and wider aberrant methylation events [Kondo et al., 1995].  
 
3.1.2 DNA methylation and reproduction 
 
Abnormal DNA methylation patterns have also been linked to several 
reproductive problems and associated diseases. During normal spermatogenesis, 
it is known that substantial epigenetic programming occurs in two waves 
[Rousseaux et al., 2005; Li, 2002; Saitou et al., 2002; Santos and Dean, 2004; 
Biermann and Steger, 2007]. Extensive erasure of DNA methylation marks 
characteristic of somatic cells is followed by the establishment of sex-specific 
patterns by de novo methylation. In one study, Houshdaran et al. used an 
extensive panel of DNA methylation assays to characterize the DNA methylation 
profile of abnormal sperm and reported elevated methylation at numerous DNA 
sequences indicating that improper erasure of somatic DNA methylation marks is 
implicated in poor quality sperm and male infertility [Houshdaran et al., 2007]. 
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Furthermore, assisted reproductive technologies that involve the manipulation 
of embryos are associated with an increased risk of children with Angelman 
syndrome and Beckwith-Wiedemann syndrome [Gicquel et al., 2003]. Molecular 
analysis of both syndromes revealed a loss of maternally imprinted methylation 
at specific gene loci on chromosome 15 and 11 respectively, implicating 
epigenetic abnormalities in the diseases [Gicquel et al., 2003]. In addition, 
epigenetic abnormalities are responsible for a large percentage of embryonic 
losses and placental hyperplasia observed in animal cloning models [Alberio and 
Campbell, 2003]. However, there is some emerging evidence that underlying 
infertility problems may play a role rather than the assisted reproductive 
technologies themselves [Doornbos et al., 2007]. 
 
3.1.3 DNA methylation and cardiovascular disease  
 
Cardiovascular Disease CVD, in particular CHD, is now the leading cause of death 
worldwide, accounting for 27% of deaths in industrialized countries and 21% of 
deaths in developing countries [Botto et al., 2001]. With genetics explaining less 
than 5% of CHD, adult lifestyle factors and epigenetics likely explain most of the 
variation [Botto and Correa, 2003]. The most obvious link between epigenetics 
and cardiovascular disease is hyperhomocysteinemia. The basis for the 
association of hyperhomocysteinemia with cardiovascular disease is unknown, 
but since elevated homocysteine concentrations can impair one carbon 
metabolism and DNA methylation, epigenetic mechanisms have been postulated 
[Kapusta et al., 1999].  
Aberrant DNA methylation (both hypo and hypermethylation) secondary to 
nutritional factors has been implicated as an early step in atherogenesis [Hobbs 
et al., 2005; van Driel et al., 2008a].  
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There are multiple reported instances of DNA hypomethylation occurring in 
atherosclerosis, specifically in the immediate atherosclerotic lesion (Hiltunen et 
al., 2002) as well as in peripheral white blood cells (Castro et al., 2003) and 
smooth muscle (Hiltunen and Yla-Herttuala, 2003; Yideng et al., 2007). Being a 
multifactorial disease, the hypothesis that hypomethylation could be a 
contributor to atherosclerosis was raised about a decade ago, although the 
aberration could also be a secondary event. As already mentioned, elevated 
homocysteine is a risk factor for the disease. Homocysteine and S adenosyl 
homocysteine are efficient inhibitors of DNA methyltransferases which could 
manifest as genomic hypomethylation, implying a secondary development. 
However hypomethylation is often observed early in atherosclerotic 
development (Lund et al., 2004) and 5-lipoxygenase and 15-lipoxygenase genes, 
key enzymes implicated in atherosclerosis development (Zhao and Funk, 2004), 
are upregulated under promoter hypomethylation (Liu et al., 2004; Uhl et al., 
2002). 
 
3.1.4 DNA methylation and Type 2 diabetes   
 
An article proposing DNA methylation profiling in diabetes reviewed indirect 
evidence that epigenetic dysregulation contributes to type 2 diabetes [Goh and 
Sum, 2010]. A recent data-mining analysis of more than 12 million Medline 
records identified epigenetic factors among the strongest statistical associations 
to type 2 diabetes. The most direct evidence implicating epigenetic dysregulation 
in human diabetes is from studies of transient neonatal diabetes (TND), a rare 
form of diabetes that presents within the first few days after birth and, although 
normally resolving within one year, often recurs later in life. Two studies recently 
showed that infants with sporadic TND show aberrant methylation at several 
imprinted genes in peripheral blood leukocytes [Zhao et al., 2012; Kantlehner et 
al, 2011].  
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Effects of parental and grandparental nutrition on diabetes risk in humans have 
been reported, suggesting transgenerational inheritance of epigenetic alterations 
that affect diabetes susceptibility [Chaudhary et al., 2012; Frantz et al., 2012]. 
Several animal models showing persistent effects of prenatal and early postnatal 
nutrition on endocrine pancreas function and gene expression suggest an 
epigenetic basis [Canani et al., 2011; Godfrey et al., 2011]. 
 
3.1.5 DNA methylation and obesity   
 
Prader-Willi syndrome is a developmental syndrome that causes hyperphagic 
obesity, hypogonadism, and characteristic facial features [Smith et al., 2011]. 
Whereas the disease most commonly results from genetic abnormalities in an 
imprinted region of chromosome 15, some sporadic cases result from aberrant 
epigenetic silencing of that region, providing a clear example of epigenetic 
dysregulation causing human obesity. Genome-wide parent-of-origin linkage 
analyses suggest that maternally imprinted loci in chromosome regions 10p12 
[Alegría-Torres et al., 2011] and 2q37 [Boyle et al., 2011] also influence human 
obesity. Moreover, imprinted genes affect the development of the 
hypothalamus, which plays a central role in regulating energy homeostasis 
[Herrera et al., 2011]. Animal models provide further illustrations that epigenetic 
dysregulation can cause obesity [Seky et al., 2012]. When mice are cloned, they 
have normal birth weights but often develop adult-onset obesity. A similar 
phenomenon, termed “large offspring syndrome,” appears to be related to 
epigenetic dysregulation in cloned sheep [Zhang et al., 2011]. Avy mice provide 
another animal model of epigenetically based obesity. Agouti protein binds 
antagonistically to the melanocortin 4 receptor in the hypothalamus. Avy/a mice 
with Avy hypomethylation therefore develop not only yellow coats but also 
hyperphagic obesity [Morgan et al., 1999]. 
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3.2. DEVELOPMENTAL ORIGIN OF HEALTH AND DISEASE 
HYPOTHESIS (DOHaD) 
 
Subsequent to the highly regulated changes during development, it has been 
generally assumed that the methylome is fairly immutable and uniform in adult 
cells. There is, however, the potential for the epigenome to be modulated by 
external factors, under certain circumstances. In the case of DNA methylation, 
there is an accumulation of evidence to suggest that exogenous effectors, 
including diet, have the ability to alter methylation either of the individual or that 
individual’s progeny. The developmental origins hypothesis [Barker et al., 1989] 
proposes Barker and colleagues that during critical periods of prenatal and 
postnatal mammalian development, nutrition and other environmental stimuli 
influence developmental pathways and thereby induce permanent changes in 
metabolism and chronic disease susceptibility. Although extensive human 
epidemiologic and animal model data support this thesis [Waterland, 2009], the 
underlying biologic mechanisms are poorly understood. 
3.2.1 Fetal programming 
 
Traditionally, the intrauterine environment has been regarded as critical only for 
prenatal development of the fetus. However, there is accumulating evidence 
showing that adverse influences during early development can increase the risk 
of developing disease in adult life. It was first observed by Barker and co-workers 
that the weights at birth were correlated with the risk of developing coronary 
artery diseases in adults [Barker and Osmond, 1986; Barker et al., 1989]. 
Subsequently, it has also been found that birth weights were associated with 
chronic diseases, such as hypertension [Curhan et al., 1996a; Curhan et al., 
1996b] and Type 2 diabetes [Hales et al., 1991; Ravelli et al., 1998]. 
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Based largely on the epidemiological data, Barker suggested an hypothesis that 
the alterations of fetal nutrition and endocrine status may result in 
developmental adaptations that permanently change the structure, physiology, 
and metabolism which then predispose individuals to cardiovascular, metabolic 
and endocrine disease in adult life [Barker, 1992; Barker, 2004]. This paradigm is 
referred to as “fetal programming”. The term “programming” refers to the 
permanent or long term effects of a stimulus or insult at a critical or sensitive 
period [Lucas, 1991]. 
Further studies in experimental animals have provided proof of principle for fetal 
programming, suggesting that intrauterine environment is important for long 
term postnatal development [Armitage et al., 2004; Gluckman and Hanson, 
2004b; Hoet and Hanson, 1999]. The most commonly used approach to study the 
effect of intrauterine environment has been to alter maternal nutrition during 
pregnancy, for example, by subjecting the pregnant animals to protein 
malnutrition. It has been shown that the mice with maternal protein 
malnutrition result in various degrees of disturbed glucose metabolism [Dahri et 
al., 1991] and cardiovascular function [Langley and Jackson, 1994] in the 
offspring. It has also been shown that other perturbations of maternal 
physiology, such as administration of corticosteroids [Dahlgren et al., 2001], 
cytokines [Nyirenda et al., 1998] or experimental reduction of uterine blood flow 
can lead to fetal programming of obesity [Jansson and Lambert, 1999; Simmons 
et al., 2001] or diabetes [Nyirenda et al., 1998; Simmons et al. 2001]. These 
phenomena were referred to as developmental plasticity of the fetus during 
pregnancy, which conveys the ability to change the structure and function of the 
fetus in an irreversible fashion during a critical time window in response to the 
environmental cue [Gluckman and Hanson, 2004a; Gluckman and Hanson, 
2004b]. The concept of fetal programming has more broadly been defined as 
developmental and evolutionary strategies, termed “predictive adaptive 
response”. This theory proposed „the developmental plasticity as adaptive 
responses to environmental cues acting early in the life cycle, but where the 
advantage of the induced phenotype is primarily manifest in a later phase of the 
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life cycle‟ [Gluckman and Hanson, 2004a; Gluckman and Hanson, 2004b]. 
Therefore, instead of causing developmental disruption immediately, the 
plasticity allows the fetus to respond to the environmental influences by 
following a developmental trajectory that may be associated with an adaptive 
advantage in utero [Gluckman and Hanson, 2008]. The resulting phenotype is 
likely to be advantageous in an anticipated future environment. The cue thus 
acts as a predictor of the nature of this environment. For instance, if the fetal 
metabolism and growth are adapted to the predicated postnatal environment by 
the nutrient supply during fetal life as the primary cue, intrauterine nutrient 
restriction will cause inappropriate fetal predictive response for subsequent 
abundance supply of nutrients in postnatal stage. Such mismatch of anticipation 
will then result in susceptibility for chronic diseases in adulthood [Gluckman and 
Hanson, 2004b] (Figure9).  
These observations highlight the importance of investigating the relationship 
between maternal-fetal interface and the fetal development. 
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Figure: DOHaD Theory: This suggested that the relationships between birth weight and 
metabolic disease arose because of the response of a growing fetus to a suboptimal 
nutritional environment. Central to this hypothesis was the suggestion that during times 
of nutritional deprivation, the growing fetus adopts a number of strategies to maximize 
its chances of survival postnatally in similar conditions of poor nutrition. Such 
adaptations include the preservation of brain growth at the expense of other tissues 
such as skeletal muscle and the endocrine pancreas, and the programming of 
metabolism in a manner that would encourage storage of nutrients when they were 
available. This has no detrimental effect and is in fact beneﬁcial to survival if the fetus is 
born into conditions of poor nutrition. Thus, in populations where there is chronic 
malnutrition, these adaptations are beneﬁcial and prevalence of metabolic disease is 
low. However, detrimental consequences of developmental programming were 
proposed to arise if the fetus was born into conditions that differed from those 
experienced in utero. The imbalance between the early and postnatal environments 
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may then conﬂict with the programming that occurred during fetal life and predispose 
the offspring to the subsequent development of metabolic diseases in adulthood 
[Gluckman and Hanson 2004]. 
 
 
3.2.2 Retrospective studies 
 
There are a limited number of epidemiological studies where associations 
between nutrition and disease outcomes have been attributed to epigenetics, 
albeit tenuously. For example, epigenetic profiling of 80 monozygotic twins 
found that variation in global and locus-specific DNA methylation and histone 
acetylation accumulated between twins with age, mirroring age-dependent 
morphological differences, or disease susceptibility discordance. A difference in 
diet between twins was given as one possible explanation [Fraga et al., 2005]. 
Also, a recent Swedish study reported a link between men starting smoking at an 
early age and a higher body mass index in their sons, which they tentatively 
attributed to epigenetics [Pembrey et al., 2006].The same laboratory assessed 
other cohorts that were exposed to poor nutrition at discrete time periods early 
in life.  Participants’ grandchildren subsequently displayed a decreased risk of 
heart disease, but only if the grandchild was of the same sex. Conversely, an 
excess of food in the grandfather produced a four-fold increase in risk of death 
from diabetes in the grandchild [Kaati et al., 2002; Pembrey et al., 2006].The sex-
specific results in particular, suggest an epigenetic influence, although changes in 
DNA methylation were not investigated. 
More robust examples are found in the Hunger Winter Families Studies. In 1944, 
the occupied Western territories of the Netherlands underwent severe famine, 
due to a particularly harsh winter and a Nazi-imposed food embargo. Throughout 
this period however, birth registries and healthcare continued and existing food 
rations were well documented. This allowed the famine to be clearly defined and 
exposed individuals to be traced. Various studies have investigated the 
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epigenetic effect of the famine on those who were in utero at that time. 
Interestingly, such individuals later displayed aberrant IGF2 imprinting, six 
decades after the event, compared to their siblings who were not exposed to 
such periconceptual shock [Heijmans et al., 2008]. Further methylated loci have 
since been shown to be differentially methylated in these individuals, often in a 
sex-specific manner [Tobi et al., 2009]. Interestingly, colorectal cancer incidence 
was decreased for individuals who were adolescents during the famine, despite 
hypermethylation of discrete loci associated with a neoplastic phenotype [Dirx et 
al., 2003; Hughes et al., 2009]. 
 
3.2.3 Experimental studies 
 
The epidemiological nature of the above studies makes delineating specific 
contributors to disease difficult, whether they be epigenetic or otherwise. More 
success has been achieved in experimental animal model systems. Agouti mice 
are characterised by a variable coat colour that is epigenetically mediated. Mice 
with the Avy (agouti, viable yellow) allele together with a wildtype allele (a) 
display a range of coats: yellow, where the agouti gene is overexpressed, through 
increasingly mottled shades due to partial agouti overexpression, to brown, 
which is referred to as psuedoagouti and which has minimal aberrant expression 
[Wolff et al., 1998]. Furthermore, ectopic expression of the agouti allele 
interferes with metabolic and endocrine systems in multiple tissues resulting in 
increased morbidity later in life; yellow and mottled mice are prone to obesity, 
cancer and diabetes, while brown psuedoagoutis are not [Wolff et al., 1999]. 
The variation in agouti gene expression is dependent upon the methylation of a 
neighbouring upstream LTR promoter, termed an intracesternal. A particle, or 
IAP [Cooney et al., 2002]. The degree of methylation in this element produces 
the coat colour spectrum [Michaud et al., 1994; Morgan et al., 1999]. 
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Intriguingly, experiments that altered maternal nutritional supplementation 
shifted the epigenetic spectrum of the mother’s litter, methyl donors such as 
methionine fed to the mother increased methylation of the IAP, suppressed 
agouti gene expression and pushed the colour range of her offspring towards the 
brown end of the spectrum. This also improved morbidity in the pups when fully 
grown [Cooney et al., 2002; Waterland and Jirtle, 2003]. Furthermore, such 
modified agouti phenotypes as a result of supplementation persisted for multiple 
generations [Cropley et al., 2006]. 
The agouti model has also been used to probe other environmental exposures, 
such as the effect of maternal alcohol consumption on developing embryos. In 
this case, early gestational exposure to ethanol produced hypermethylation of 
the Avy allele and produced more offspring with a pseudo-agouti-coloured coat 
[Kaminen-Ahola et al., 2010]. 
More nebulous effectors like behaviour have also been shown to influence DNA 
methylation and produce different phenotypic trajectories. Rats that show high 
levels of care and attention towards their pups in the first week of life, in the 
form of licking and grooming, produce lower stress responses in the offspring as 
adults [Francis et al., 1999; Liu et al., 1997]. 
Cross-fostering of pups to mothers that did not groom as much created higher-
stressed pups in adulthood. This suggested an epigenetic rather than genetic 
mechanism. High rates of maternal licking and grooming altered the expression 
of multiple genes in the hippocampus of the young, including increased 
hippocampal glucocorticoid receptor (GR) expression, a protein implicated in 
short and long term response to stressors [Weaver et al., 2004; Weaver et al., 
2005]. Differences in the DNA methylation and histone acetylation of the GR 
promoter were apparent by day eight in the pups between high care and low 
care mothers and these differences persisted through adulthood. Additionally, 
infusing trichostatin, a histone deacetylase inhibitor, into the brains of adult 
offspring of low care mothers increased histone acetylation, decreased cytosine 
methylation in the GR promoter and increased expression of the gene. Response 
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to stress became comparable to rats who received high levels of licking and 
grooming as pups [Weaver et al., 2004]. Conversely, injecting methionine into 
the brains of offspring from high-care mothers increased the methylation state 
of the GR promoter, decreased GR expression and increased their anxiety 
[Weaver et al., 2005; Weaver et al., 2006]. Methionine treatment altered 
methylation patterns of a further 300 hippocampal genes, suggesting that such a 
phenomenon was not limited to the GR locus [Weaver et al., 2006]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
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4. AIMS OF PhD PROJECT 
 
In the light of all the literature reports shown in previous chapters is evident that 
the etiology of the CH is still largely unclear. In this scenario, epigenetic 
mechanisms and in particular an aberrant DNA methylation may explain the 
increased risk of CH in premature infants and/or with low birth weight and 
intrauterine growth retardation. We suggested that adverse maternal conditions 
such as diet or others adverse lifestyle factors influence the establishment of a 
proper methylation program on fetus during pregnancy. This leads to an early 
fetal adaptation to extrauterine life, in which changes in pathways involved in 
the development and in metabolism play an important role. This adjustment 
could be associated with complications during pregnancy and defects in growth 
and thyroid development. For that reasons we analyze the global and the gene-
specific DNA methylation profile of affected children with congenital 
hypothyroidism with preterm birth and intrauterine growth delay, against term 
and preterm healthy controls.  
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CHAPTER V 
5. MATERIALS AND METHODS 
 
In briefly, after the collection of blood sample of cases and controls (5.1.1), the 
genomic DNA was extracted (5.1.2) and quantified (5.1.3) to test the quality and 
concentrations for the DNA methylation analysis.  
The DNA was than treated with bisulfite to converts the unmethylated cytosine 
to uracil, allowing to discriminate between methylated cytosine (M) and 
unmethylated (U) (5.2.1).  
We than performed the DNA methylation analysis by the Illumina 
HumanMethylation27 BeadChip Array (5.2.2).  
The raw data of methylation were exported and validated by the GenomeStudio 
software to normalizing and selects the samples than not reached the standards 
of quality (5.3.1 and 5.3.2).  
The clean data were also analyzed by several statistical methods to study the 
global and the gene-specific methylation patterns (5.3.3).  
Finally the selected genes that are differentially methylated between cases and 
control were studied by their biological functions and pathways involved (5.3.4).  
Ultimately, we studied the role of maternal folate deficiency by the analysis the 
DNA of nine mothers for MTHFR polymorphisms (5.4.1). 
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5.1 SAMPLES COLLECTION AND DNA EXTRACTION 
 
5.1.1 Recruitment of patients 
 
Sixty-eight peripheral-blood samples from CH-subjects, healthy children and 
parents were collected between 2008 and 2010 thanks to the collaborations of 
the Pediatric Units of San Raffaele Hospital of Milan and Bolzano Hospital. All 
participants were informed and agreed to participate at this projects. The details 
about the clinical features of patients and the design of the DNA methylation 
study are reported in the section of results. 
 
5.1.2 DNA isolation from peripheral blood samples 
 
Fasting blood samples were collected in EDTA-Vacutainer tubes and immediately 
chilled on ice before they were centrifuged at 4000 x g for 10 min at 4ºC. DNA 
was isolated from the stored frozen blood samples according the manufacturer’s 
protocol for the PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN): 
Cell Lysis  
1. Add 300 μl whole blood (or bone marrow) to a 1.5 ml microfuge tube 
containing 900 μl RBC Lysis Solution. Incubate 1 minute at room temperature 
and invert gently 10 times during the incubation. 
2. Centrifuge for 20 seconds at 13,000-16,000 x g. Remove as much supernatant 
as possible with a pipette leaving behind the visible pellet and about 10-20 μl of 
the residual liquid. 
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3. Vortex the tube vigorously for 10 seconds to resuspend the white cells in the 
residual liquid;  
4. Add 300 μl Cell Lysis Solution and 3uL 10ng/uL proteinase K (not included in 
kit) to the resuspended cells and pipet up and down to lyse the cells. Incubate at 
55°C over night.   
RNase Treatment   
1. Add 1.50 μl RNase A Solution to the cell lysate. 
2. Mix the sample by inverting the tube 25 times and incubate at 37°C for 15’ 
Protein Precipitation 
1. Cool sample to room temperature. 
2. Add 100 μl Protein Precipitation Solution to the cell lysate. 
3. Vortex vigorously at high speed for 20 seconds to mix the Protein Precipitation 
Solution uniformly with the cell lysate. 
4. Centrifuge at 13,000-16,000 x g for 1 minute. The precipitated proteins will 
form a tight, dark brown pellet.  
DNA Precipitation 
1. Pour the supernatant containing the DNA (leaving behind the precipitated 
protein pellet) into a clean 1.5 ml microfuge tube containing 300 μl 100% 
Isopropanol (2-propanol). 
2. Mix the sample by inverting gently 50 times. 
3. Centrifuge at 13,000-16,000 x g for 1 minute; the DNA will be visible as a small 
white pellet. 
4. Pour off supernatant and add 300 μl 70% Ethanol and invert the tube several 
times to wash the DNA pellet. 
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5. Centrifuge at 13,000-16,000 x g for 1 minute. Carefully pour off the ethanol.  
6. Invert and drain the tube on clean absorbent paper for 5 seconds. 
DNA Hydration 
1. Add 50 μl DNA Hydration Solution and vortex 5 seconds to mix. 
2. Incubate sample at 65°C for 5 minutes to accelerate rehydration. Note: 
samples may be incubated at 65ºC for up to 1 hour. 
3. Vortex 5 seconds and spin to collect sample at the bottom of the tube. 
4. Store DNA at 4°C. For long-term storage, store at –20° or –80° C. 
 
5.1.3 DNA quality and quantity 
 
A NanoDrop® ND1000 Spectrophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE, USA) was used to measure the DNA concentration and the 
absorbance ratio (A260/A280). When DNA is extracted from biological samples, 
protein frequently remains in the DNA solution. Protein is tightly bound to DNA, 
and complete removal of protein is not always possible. In general, the peak of 
UV absorption is at 260 nm for DNA and at 280 nm for protein. Thus, when a 
solution contains both DNA and protein, absorbance at 260 nm is mainly due to 
the DNA present, and absorbance at 280 nm is due to protein. A pure sample of 
DNA has the ratio at 1.8 and is relatively free from protein contamination. 
Generally, the expected ratios for extracted DNA samples should range from 1.7–
2.0 [Hebron et al., 2009]. 
To visualize DNA quality, 1 l of each DNA was loaded on a 1% agarose gel. The 
extracted DNA sizes were estimated using the DNA marker of GeneRuler™1 kb 
Plus (Fermentas, Glen Burnie, MD, USA). A digital image was taken under UV 
light in a Universal Hood II (Bio-Rad, Hercules, CA, USA). 
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5.2 DNA METHYLATION ANALYSIS 
 
5.2.1 DNA bisulfite treatment 
 
The process of bisulfite conversion of DNA exploits the different sensitivities of 
cytosine and 5-methylcytosine (5-MeC) to deamination by bisulphite under acidic 
conditions, in which cytosine undergoes conversion to uracil, whereas 
methylated cytosine is non-reactive. The efficiency of the reaction is well 
documented with approximately 99% of unmethylated CpGs undergoing 
conversion and 99% of methylated CpGs being protected from conversion 
[Patterson et al., 2011]. Bisulfite treatment of 500ng to 1μg DNA per sample was 
done using the EZ DNA Methylation-Gold Kit (Zymo Research) according to the 
manufacturer’s instructions prior to the Illumina Infinium DNA Methylation 
array: 
1. Add 130 µl of  CT Conversion Reagent solution to each 20 µl sample in the  
Conversion Plate.  Mix the samples by pipetting up and down.  
2. Seal the Conversion Plate with Cover Film. Place the plate in a thermal cycler 
and perform the following steps:  
1. 98°C for 8 minutes  
2. 64°C for 3.5 hours  
3. 4°C storage for up to 20 hours  
3. Add 400 µl of M-Binding Buffer to the wells of a Silicon-A™ Binding Plate on a 
provided Collection Plate.  
4. Load the samples (from Step 2) into the wells of the  Silicon-A™ Binding Plate 
containing the M-Binding Buffer.  Mix by pipetting up and down.  
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5. Centrifuge at ≥ 3,000 x g for 5 minutes.  Discard the flow-through and reuse 
the Collection Plate for the following wash steps.  
6. Add 400 µl of M-Wash Buffer to each well of the plate.  Centrifuge at ≥ 3,000 x 
g for 5 minutes.  
7. Add 200 µl of M-Desulphonation Buffer to each well and let the plate stand at 
room temperature (20°C - 30°C) for 15 - 20 minutes, then centrifuge at ≥ 3,000 x 
g for 5 minutes.  Discard the flow-through.  
8. Add 400 µl of M-Wash Buffer to each well of the plate.  Centrifuge at ≥ 3,000 x 
g for 5 minutes.  Add another 400 µl of M-Wash Buffer and centrifuge for an 
additional 5 minutes.  
9. Place the Silicon-A™ Binding Plate onto a provided Elution Plate.  Add 30 µl of 
MElution Buffer directly to each well.  Wait 5 minutes, then centrifuge for 3 
minutes at ≥ 3,000 x g to elute the DNA.  
The converted DNA was resuspended in 20 μl of TE buffer and stored at −80°C 
until the samples were ready for analysis. 
5.2.2 Infinium Assay for Methylation 
 
DNA methylation analysis was conducted using the Illumina® Infinium Human 
Methylation27 BeadChip. Each HumanMethylation27 BeadChip consists of 12 
arrays, and up to 4 bead chips were processed simultaneously. The assay allows 
the interrogation of over 27,000 CpG sites located within the proximal promoter 
regions of over 14,000 consensus coding sequences (CCDS) genes throughout the 
genome [Bibikova et al., 2009]. In addition, the assay includes 110 miRNA 
promoters and also includes imprinted genes (see table 2). The standard protocol 
provided by Illumina® was used for DNA methylation analysis.  
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Briefly, 4 μl of bisulfite converted DNA was isothermally amplified at 37ºC 
overnight. The amplified DNA product was fragmented by an endpoint enzymatic 
process. Fragmented DNA was precipitated, resuspended, and applied to an 
Infinium Human Methylation27 BeadChip and hybridized overnight. During 
hybridization, the amplified and fragmented DNA samples anneal to specific 
oligomers that are covalently linked to over 27,000 different bead types.  
Each bead type corresponds to the nucleotide identity and thus the methylation 
status of a bisulfite-converted cytosine in a specific CpG site. The bead chips 
were then subjected to a single-base extension reaction using the hybridized 
DNA as a template incorporating fluorescently labeled nucleotides of two 
different colors, each corresponding to the cytosine (methylated) or uracil 
(unmethylated) identity of the bisulfite-converted nucleotide at a specific CpG 
site (figure 10).  
The fluorescently stained chip was imaged by the Illumina® BeadArray Reader. 
The Illumina® Genome Studio program was used to analyze BeadArray data to 
assign site-specific DNA methylation β-values to each CpG site.  
The proportion of methylation (β) for each subject at each CpG site was 
computed by first subtracting the background signal intensity of negative 
controls from both the methylated and unmethylated signals and then taking the 
ratio of the methylated signal intensity to the sum of both methylated and 
unmethylated signals. Thus, the β-value is a continuous variable ranging between 
0 and 1. 
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Table 2: CpG sites represented on the Illumina HumanMethylation27 BeadChip. 
 
 
 
 
Fig 10: Workflow of the Illumina Infinium technology.  
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5.3 ANALYSIS OF DNA METHYLATION DATA 
 
5.3.1 Experimental design and quality control 
 
A total of one batch of five bead chips (60 samples) was assayed. Cases and 
controls were randomly placed within the bead chips. Replicate samples were 
included in each batch for quality control and normalization measures. All 
replicate samples achieved a correlation coefficient of greater than 0.985 (data 
not shown).  
Using the Illumina® Genome Studio, background adjusted β-values and assay 
control probe information was used for initial quality control. Subjects were 
required to pass three initial quality control criteria in order to be included in 
further analysis:  
1) Subjects achieved a 95% CpG site call rate, which equals 26,250 sites called at 
an α<0.05 significance level;  
2) Background signal for each subject was under 1000 units, determined from 
the controls dashboard in Genome Studio; 
3) Clear separation was observed in the non-polymorphic controls, also 
determined from the controls dashboard.  
One sample did not meet these criteria and was removed from the analysis. 
Individual CpG sites were examined using the detection pvalue metric provided 
by Illumina® in which the signal generated from each CpG site is compared to 
negative controls. A threshold of p<0.05 was used as a cutoff.  
CpG sites that did not reach this threshold were eliminated from the analysis. 
Using this criterion, 329 of 27,578 CpG sites (1.2%) had missing or invalid β- 
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values in ten or more samples; these sites were dropped from subsequent 
analysis, leaving 27,249 CpG sites among 58 subjects.  
5.3.2 Principal Component Analysis 
 
Principal component analysis (PCA) was performed on the β-value data matrix of 
58 subjects (rows) and 27,249 CpG sites (columns). Data were log it transformed 
prior to PCA and subsequent association testing. As described above, 329 CpG 
sites with missing or invalid β-values in ten or more samples were removed from 
the data; before performing PCA, any remaining missing β- values were imputed 
using k nearest neighbor averaging (Troyanskaya et al., 2001). The first 20 
principal components (PCs) explain 62.8% of overall variance in the logit-
transformed β-value matrix, and no single PC among the remaining 347 PCs 
explains more than 0.34%. 
5.3.3 Determination of differentially methylated CpG sites 
 
After initial quality control and PCA of the β value data, a sample of 58 subjects 
(31 cases and 27 controls) was tested for association between disease status (i.e. 
case/control) and maternal gene-specific methylation. In this analysis, each CpG 
site was tested for association by regressing its logittransformed β value on 
case/control status using multiple linear regression models. Additional covariates 
included in these models were experimental batch (as a factor), bisulfite-
conversion (BSC) efficiency, age, gestational age, birth weight and TSH levels. BSC 
efficiency for each subject has two channels, red and green. The red and green 
channels are highly correlated but are not sufficiently collinear, thus both 
channels were included in the models. 
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Under standard theory a t-statistic, derived from the least-squares estimate of 
the case/control parameter and its standard error, was compared with the 
theoretical t-distribution to test the null hypothesis of no association between 
disease status and site-specific methylation, H0 : c j= 0, where j=1,…,27,249 
indicates the CpG site. Because of the potential for spurious association due to 
chip bias, however, a randomization testing approach was used to evaluate 
statistical significance. For each pseudo-dataset, disease status was randomized 
in a two-stage process for each chip. First, disease status was randomly 
permuted among the subjects on that chip, and then with 50% probability, 
disease status was swapped between case and control for all subjects on the 
chip. In each pseudo-dataset, therefore, each subject was equally likely to be 
assigned case or control status, which means that, H0 : c j= 0 is known to be 
(synthetically) true. However, because the randomization is performed 
separately within chips, the structure of the experimental design, and therefore 
the chance for spurious disease association due to chip effect, is retained. The 
empirical null distributions resulting from this randomization approach had 
heavier tails than the theoretical null distribution, leading to less significant p-
values. The randomization approach is therefore a conservative approach and 
properly controls type-I error in the presence of chip-to-chip variation of β-
values. To properly account for the large number of statistical tests being 
performed, false discovery rate (FDR) q-values [Teschendorff et al., 2009] were 
computed for each CpG site. In our context, FDR is the proportion of detected 
disease associations (under a given hypothesis testing procedure) that are false, 
while the q-value is defined as the minimum FDR at which a given test can be 
considered significant. The q-value is therefore the FDR equivalent of the p-value 
and was computed using the qvalue package in the R statistical programming 
environment, under default settings [R Development Core Team, 2008]. 
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5.4 Biological Processes and Pathway analysis 
 
 
5.4.1 Functional annotation of gene lists   
 
Based on the results from our association testing, a list of differentially 
methylated CpG sites with p-values less than 0.005 was generated. The CpG sites 
of interest were mapped to their corresponding genes and the list of genes were 
then tested for potential overlaps with biological processes and pathways using 
the freely available Database for Annotation, Visualization and Integrated 
Discovery (DAVID) database and KEEG pathway database were used for analyzing 
large lists of genes to mine for functionally related groups of genes and genes 
within pathways [Subramanian et al., 2005]. The software is designed to evaluate 
microarrays at the level of gene sets. Gene sets are defined as groups of genes 
that share common biological function, chromosomal location or regulation. The 
gene set database used in the analysis is established based on prior biological 
knowledge. 
 
5.4.2 Individual gene information   
 
The National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/) and GeneCards (http://www.genecards.org/) 
were used to gather information on the functions, published work and general 
information for individual genes. 
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5.5 ANALYSIS OF MTHFR POLYMORPHISMS 
 
The SNP was typed by direct DNA sequencing using primers flanking the A1298C 
and T1317C polymorphism region. We used the (CAAGGAG-GAGCTGCTGAAGA) 
forward and the (CCACTCCAG-CATCACTCACT) reverse primers, which result in a 
128 base-pair (bp) fragment. The amplification conditions for 200 ng of DNA 
were: 10 mM of Tris-HCl (pH 8.4); 50 mM of potassium chloride (KCl); 2.0 mM of 
magnesium chloride (MgCl2); 0.2 mM each of deoxynucleotide triphosphate 
(dATP, dCTP, dGTP, dTTP); 0.2 pmol/μL of each primer, and 1.0 U of Taq DNA 
polymerase. The initial denaturation cycle at 94°C for 4 minutes was followed by 
30 amplification cycles at 94°C for 60 seconds for DNA denaturation, 60°C for 50 
seconds for annealing of the primers, and 72°C for 60 seconds for chain 
extension. A last cycle of 10 minutes at 72°C was performed for final extension of 
the chains. For sequencing by ABI PRISMA 3100 Genetic Analyzer (Applied 
Biosystems), we used a forward primer (ForwardC) according to Ranjith et al. 
(2003). The amplification product was purified using a QIAquick PCR Purification 
Kit (Qiagen, Germany), according to the manufacturer’s instructions. The 
sequencing reaction was performed with a BigDye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems, UK), according to the manufacturer’s 
instructions. Analysis was based on the chromatograms reproduced by the 
automated sequencer. 
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CHAPTER VI 
6. RESULTS 
6.1 DESIGN OF DNA METHYLATION STUDY 
 
6.1.1 Statistical methods  
 
Unsupervised hierarchical clustering of samples and analysis of DNA methylation 
were done using the Illumina GenomeStudio® software. Differentially methylated 
probes in the Illumina array from each comparison were identified using 
Siggenes package from R with a cut-off of false discovery rate (FDR) <0.1% and 
Differential Score (DS)> 13. FDRs were generated after comparison of 1000 
random permutations between samples. DS of 13, corresponding to a p value of 
0.05, takes into account background noise and sample variability. Pearson linear 
correlation was used to determine the similarity of DNA methylation profiles 
between samples. The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) and Kyoto Encyclopedia of Genes and Genomes (KEGG), were 
used for gene ontology and pathway analysis using total number of genes 
presented in the array as a background for comparison (Dennis et al. 2003; 
Huang da et al. 2009). The results are presented as mean (SEM) or proportions. 
Student’s t-test, chi-squared test, analysis of variance and rank-sum test were 
used to test group differences. A p-value<0.05 was considered significant. The 
association between covariates or potential confounders and outcome were 
tested using simple, linear regression or ANOVA. 
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6.1.2 Collections of CH and control subjects  
 
Thanks to the partnership of the Pediatric Units of Hospital of Bolzano and San 
Raffaele Hospital of Milan, we collected a total of 31 children born prematurely 
with CH (cases group) and 28 term/preterm healthy subjects (controls group). As 
reported in detail in table 3, cases and controls have comparable ages at sample 
collection and gender proportions.  
Most of them were born from spontaneous conception while the remaining 20% 
by in vitro fertilization techniques. The percentages about only child/twins per 
reproductive event are 29-71 for CH-cases and 43-57 for controls.  
Focused on twin pairs data, the fraction of monozygotic and dizygotic twins 
(MZ/DZ) are 41/59 for CH-cases and 19/81 for ctrls groups. Based on thyroid 
phenotype, the 64% of affected subjects are concordant while the others are 
discordant for CH.  
According to the clinical data at birth, all of CH-cases were born preterm while 
about half of healthy controls were premature and half born at term. The 65% of 
affected children was born small for gestational age whereas the majority of 
controls had an acceptable intrauterine growth. Concerning the thyroid 
phenotype, the 42% of the cases showed a subclinical hypothyroidism and the 
58% exhibit an overt hypothyroidism. All of them had an in situ gland with 
volume and free-T4 values within normal limits.  
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CH-CASES CONTROLS p-VALUE
Number of subjects
N 31 28
Age at sample's collection
years 5.1 (2.6) 5.7 (2.8) 0.91
Gender
Male % 58 47
Female % 42 53
Conception
Spontaneus % 87 81
FIVET/IUI % 13 19
Number of child/reproductive event
Only child % 29 43
Twins % 71 57
Twin pairs data
MZ/DZ % 41/59 19/81
discordance/concordance for CH % 36/64 50/-
Gestational Age
Preterm birth % 100 57
At term birth % - 43
Percentile of fetal growth
Small for Gestational Age (SGA) % 65 29
Acceptable for Gestational Age (AGA) % 35 71
Serum TSH
Subclinical Hypothyroidism (SH) % 42 -
Overt Hypothyroidism (OH) % 58 -
Free T4
ng/L 1.04 (0.43) -
GENERAL FEATURES 
CLINICAL DATA AT BIRTH
 
Table 3: General characteristics and clinical data of subjects enrolled in this study. The 
features are reported as numbers or percentages. To show a significant difference of the 
age at sample collection between cases and controls, a p-value are reported.  
 
 
To understand the relationship between DNA methylation and prematurity 
and/or the intrauterine growth delay associated with the onset of CH, we divided 
the subjects about their a) gestational age, b) intrauterine growth and c) thyroid 
function, and performed three independent DNA methylation studies.  
These approaches can let to find which factors that have undergone aberrant 
methylation, affects the state related to prematurity or intrauterine fetal growth 
or are direct linked to thyroid development of at thyroid hormone action at 
peripheral level (Table 4 a, b, c).  
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The details of the DNA methylation analysis and subjects’ categorization are 
reported in the following chapter (6.1.4).  
 
 
Table 4: Categorization of cases and controls based on their clinical data at birth and 
thyroid function. a) Gestational Age approach: CH-VPB, CH-PB vs C-VPB, C-PB and C-TB; 
b) Intrauterine growth approach: CH-SGA, CH-AGA vs C-SGA and C-AGA; c) Thyroid 
function approach: SH and OH cases vs C-PB and C-TB. 
 
 
6.1.3 Design of DNA methylation studies  
 
The DNA methylation analysis by Illumina’s array platform was the same for each 
approach. This method allows quantifying the DNA methylation levels of 27,252 
CpG sites belonging to 14,495 genes. The majorities of these sites (73%) is 
localized into “CpG islands” of promoter of target genes and are characterized by 
the direct action of methylation on gene expression. The remained 27% are 
called “non-CpG island” sites and are localized into non-promoter regions also 
called non-coded DNA such as repetitive elements (Line and Alu repeats) and 
intronic sequences, whereas the DNA methylation acts indirectly on gene 
expression by recruiting the complexes responsible of chromatin condensation 
[Shen et al, 2009]. 
The results regarded CpG island sites and non-CpG islands site as well as the 
autosomes and the X-linked CpG sites were reported separately, since these 
regions have different DNA methylation levels (figure 11).   
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Figure 11: DNA methylation levels of ChX from female and male and of autosomes from 
CpG island and Non-CpG island sites. Boxes represent the global methylation levels (0 to 
100% of AVG Beta) and the red line shows the mean values.  
 
 
In briefly, we firstly applied an ANOVA statistical method of standard deviations 
of AVG Beta values from cases and controls groups. As previously described, the 
presence of potential confounders, such as the ratio of only child/twin pairs or 
the ages at sample collection, can influence the DNA methylation patterns and 
the internal variability of groups [Hwang and Park, 2009]. In fact, the genetic 
similarities of twins as well as genetic differences of single child can influence the 
internal variability of groups and subsequently the DNA methylation analysis. 
This method represents a good index of the variability between and within 
groups, where non-significant differences between cases and controls indicate a 
good homogeneity of samples (6.2.1).  
Subsequently we performed an analysis of clustering to display the Euclidian 
distances of cases and controls. This analysis can allow us to see the closeness or 
discrepancy between subjects based on their methylome (6.2.2). 
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Then, we analyzed the global DNA methylation profile of “CpG island sites” and 
“non-CpG island sites” of autosomes and sexual chromosome.  
We compared the DNA methylation trends by correlating the AVG beta values 
with the 19.252 CpG island sites and the 7.234 non-CpG island sites. The 
graphical representation indicates roughly how many CpG sites and how much 
are differentially methylated between cases and controls (6.3.1).  
A more accurate estimate is obtained with the comparison of the mean AVG 
beta values of groups and a t-test method allows us to find which subjects have a 
statistically significant difference of methylation (6.3.2).           
Afterwards, we performed a gene-specific methylation analysis to select the sets 
of differentially methylated genes (DMGs) that are hypo- or hypermethylated in 
CH-cases groups than controls (6.4.1). Through a differential score plot analysis 
we exported a sets of genes with FDR<0.01, Diff Score <0.05 and AVGdeltaBeta> 
5% (for details of statistical analysis see Materials and Methods).  
Subsequently, to find which factors are associated to epigenetic changes we 
selected a set of genes in common between the three approaches and clustered 
CH-patients for these DMGs (6.4.2) 
The peculiar characteristics of DMGs were investigated by their CpG sites 
locations, chromosomes distribution and imprinted status with GeneImprint 
Software (6.4.3).  
In the 6.4.4 paragraph we described the genetic analysis of MTHFR 
polymorphism because these variants are reported to be involved in folate 
deficiency, pregnancy complications and birth defects.  
In the last section (chapter 6.5.1), by the ontology enrichment analysis, the 
DMGs were categorized by their biological processes with David Gene Functional 
Database and KEEG Pathway software. Finally, we selected a list of “top genes” 
which are particularly interesting for further studies (6.5.2).  
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These analysis let to identify the biological pathway affected on aberrant DNA 
methylation, and can potentially explains the higher predisposition of the onset 
of congenital hypothyroidism associated with premature birth and/or 
intrauterine fetal growth impairment. 
 
6.1.4 Categorization of subjects according to their clinical data 
 
a) Gestational age approach: we used the last menstrual period to estimate 
gestational age (GA) of infants. We divided cases and controls into two and three 
groups respectively, depending on the severity of prematurity: Very Preterm 
Birth with 32 completed weeks or less (VPB), Preterm Birth with 33 to 37 weeks 
(PB) and Term Birth with 38 to 40 weeks of gestation (TB). As reported in table 5, 
there’s no significant difference about the ages at sample collection of 
subgroups. Interestingly, the TSH-levels of CH-PB are significant higher then CH-
VPB. No linear correlation was found about GAs and AVG Beta levels in affected 
infants both for CpG island and Non-CpG island sites (figure 12). 
 
 
 
Table 5. Clinical data of Gestational Age approach. The details about the age at sample 
collection, GA and TSH values are reported as a mean and in parentheses are shown the 
standard deviations. CH-PB subjects have TSH levels significant higher than CH-VPB 
(*p<0.05). 
 
 
 
GENDER (m/f)
AGE AT SAMPLE 
COLLECTION (years)
GESTATIONAL AGE 
(weeks)
TSH (g/ml)
CASES GROUP VPB 8/4 6.5 (2.57) 30.6 (2.12) 9.16 (5.65)
PB 10/9 5.3 (2.29) 35.5 (1.60) 50.4 (78.63)*
CONTROLS 
GROUPS
VPB 3/6 6.4 (2.69) 30.3 (2.07) n
PB 3/3 6.6 (3.6) 34.5 (1.23) n
TB 7/5 5.2 (2.22) 39.2 (1.56)
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Figure 12. Distribution of GAs and AVG Beta values of CH children. No linear correlation 
was found both for CpG island and Non-CpG island sites. 
 
 
 
 
b) Intrauterine growth: birth weight (BW) and gestational age (GA) of these 
children are compared with reference standards for the normal spread of 
“gestation and weight-for-gestational age at birth. 
 
Infants are considered Small for Gestational 
Age or SGA when the gestational age/birth 
weight ratio (GA/BW ratio) was below of 10th 
percentile than standard curve; while, a normal 
intrauterine development or Appropriate for 
Gestational Age or AGA has a GA/BW ratio 
between 10th and 90th percentile [Milde et al., 
2006]. 
 
 
According to the percentile of intrauterine growth we categorized both cases and 
controls as SGA and AGA. As shown in table 6, no significant differences are 
found in the age of sample collection or at the TSH levels. No linear correlation 
was found about percentiles of intrauterine growth and AVG Beta levels of 
affected subjects, both for CpG island and Non-CpG island sites (figure 13). 
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Table 6: Clinical data of Intrauterine Growth approach. The details about the age at 
sample collection, GA, BW, percentile and TSH values are reported as a mean and in 
parentheses are shown the standard deviations.  
 
 
Figure 13: Distribution of percentiles of intrauterine growth and AVG Beta values of CH 
children. No linear correlation was found both for CpG island and Non-CpG island sites. 
 
 
c) Thyroid function: it was assessed through the measurement of thyrotropin 
(TSH) and the free thyroxin (fT4) levels. Serum TSH level is generally considered 
the best screening test for thyroid disease; this test has proved to be both 
sensitive and specific. In this study, the Pediatric Units of Bolzano and Milan had 
routinely performed thyroid function test using radioimmunoassay for TSH and 
fT4 measured within the first 10 days of life and repeated every 2 to 4 weeks 
after the first test [Gruters and Krude, 2011].  
The newborn thyroid capabilities was considered abnormal when the serum-TSH 
is higher than 4 U/ml (infant normal range, 0.5 < TSH < 4 U/ml) and fT4 was 
normal or lower than 0.8 ng/L (infant normal range, 0.8 < fT4 < 1.8). Considering 
GENDER (m/f)
AGE AT SAMPLE 
COLLECTION (years)
GESTATIONAL AGE 
(weeks)
BIRTH WEIGHT 
(g)
PERCENTILE 
(th)
TSH (g/ml)
CASES GROUP SGA 11/9 5.53 (2.51) 33.8 (2.4) 1427 (466.3) 3.5 (2.3) 32.6 (57.7)
AGA 8/3 5.5 (2.83) 32.9 (3.6) 1964 (644.7) 23 (19.8) 42.3 (83.6)
CONTROLS 
GROUPS
SGA 3/3 6.2 (2.26) 32.6 (1.94) 1452.5 (405.5) 4.25 (3.8) n
AGA 12/8 5.6 (2.76) 36.5 (4.4) 2720 (850.3) 57.8 (36.6) n
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this TSH cut-off, we categorized the affected infants of cases group as Subclinical 
Hypothyroidism (CH-SH) with a TSH value between 4 to 10 U/ml and Overt 
Hypothyroidism (CH-OH) with a TSH value greater than 10 U/ml, where as the 
controls group was divided as preterm birth (C-PB, GA< 37 weeks) and term birth 
(C-TB, GA>37). Unfortunately, we were not able to recall a complete data 
concerning the presence or absence of autoantibodies against thyroglobulin and 
tireoperoxidase and how many subjects were treated with L-thyroxine. As 
reported in Table 7, significant differences are found when compared the GA and 
BW of CH-SH and the others groups. Also in this case, CH children don’t show a 
direct link between TSH levels and AVG Beta values for CpG island and Non-CpG 
island sites (figure 14). 
 
 
Table 7: Clinical data of Thyroid Function approach. The details about the age at sample 
collection, GA, BW, percentile and TSH values are reported as a mean and in 
parentheses are shown the standard deviations. Significant differences (*p<0.05 and 
**p<0.001) about GA and BW of -SH than OH, C-PB and C-TB. 
 
 
 
Figure 14: Distribution of TSH and AVG Beta values of CH children. No linear correlation 
was found both for CpG island and Non-CpG island sites. 
 
GENDER (m/f)
AGE AT SAMPLE COLL. 
(years)
GESTATIONAL AGE 
(weeks)
BIRTH WEIGHT 
(g)
TSH (U/ml)
CASES GROUP SH 9/3 6,6 (2,47) 32,1 (2,71)* 1299 (417,7)** 6,02 (1,47)
OH 9/10 5,2 (2,89) 34,6 (3,07) 1793 (596,5) 60,4 (78,83)
CONTROLS GROUP PB 6/10 6,1 (2,29) 32,4 (2,76) 1625 (487,9) n
TB 7/5 5,3 (3,8) 39,3 (2,1) 2652 (679,5) n
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6.2 ANOVA STATISTICAL ANALYSIS 
 
The ANOVA analysis of autosomes between cases and controls groups of 
gestational age and thyroid function approaches don’t shown statistically 
significant differences of standard deviations, for both CpG island and a non-CpG 
island sites. The intrauterine growth approach analysis has revealed that affected 
infants with AGA have a significant internal variance (*p<0.05) when compared 
with the C-SGA group about CpG island sites.  
When we compare separately the Chr-X values of standard deviations, we found 
some differences between cases and ctrls: 
 CpG island sites about female and male CH-VPB vs C-PB and C-TB  
 CpG island sites about female and male CH-SGA vs C-SGA and at Non-CpG 
island  sites of female CH-SGA versus C-AGA 
 CpG island sites of female CH-SH vs C-PB and C-TB, and at Non-CpG island  
sites of male CH-OH than C-TB 
 
These results may be due to the small numbers of subjects in CH-AGA and the 
different fractions of females and males. This means that the following studies of 
global and gene-specific methylation status between these subgroups may be 
influenced (figure 15).  
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Figure 15: ANOVA analysis of internal variance. Gestational age approach: significant 
differences of mean standard deviation about females and males Chr X of CH-VPB versus 
C-PB and C-TB for CpG island sites. Intrauterine growth approach: p<0.05 of CpG island 
sites of autosomes between CH-AGA and C-SGA; for female and male Chr X between CH-
SGA and C-SGA; p<0.05 of Non-CpG island sites of male Chr X about IC-SGA and C-AGA. 
Thyroid function approach: significant differences of CpG island sites of female Chr X 
between CH-SH and C-PB and C-TB and about Non-CpG island sites of male Chr X 
between CH-SH and C-TB. 
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6.3 CLUSTERING OF SUBJECTS 
 
After background adjustment and normalization, we performed unsupervised 
hierarchical clustering with all the groups based on a distance measure of 1-r, 
where r is the Pearson correlation coefficient between different samples. As 
display in figure 15, for all of the three approaches, cases and controls are 
distributed according to their features at birth. In particular we have seen that 
affected children with preterm birth, acceptable intrauterine growth and overt 
hypothyroidism clustered alone than other groups. CH-children with very 
preterm birth and intrauterine growth delay are distributed between controls 
and other cases, while SH cases are localized with preterm and term controls.  
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Figure 16: Clustering on Euclidian distances of cases and controls for the three study 
approaches. 
 
 
Interestingly, when categorized separately the 31 cases and 28 ctrls, we found 
that 9/12 TB controls clustered together while PB controls are distributed 
randomly (data not shown). Focused affected patients, the only child with 
percentile of growth <10th and comparable levels of TSH are localized closely. On 
the contrary, CH subjects with a normal intrauterine development are relatively 
casually distributed. Concordant twin pairs from cases and controls clustered 
together while for discordant twin pairs, affected twin with TSH<10 U/ml 
clustered with his brother, whereas CH-twin with TSH>10 U/ml is localized far 
from healthy twin. 
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6.4 GLOBAL DNA METHYLATION ANALYSIS 
 
6.4.1 Representation of DNA methylation trends 
 
As expected, the correlation of probes methylation values between different 
sample groups is consistent with that observed in the cluster analysis. The 
analysis of global methylation data between cases and controls shows that both 
CpG island and non-CpG island sites have methylation profiles not fully 
overlapping (figure 17): 
 
 CpG island methylation trends: in all three studies, it appears that CpG 
sites that show the largest differences in methylation are those which 
are physiologically hypomethylated. In fact, approximately 3.000 of 
19.252 CpG sites that have a different methylation status between cases 
and controls ranges from 10 to 20% of AVG Beta.  
 
 Non-CpG island methylation trends: on the contrary in this case, the 
major differences are found in CpG sites that are hypermethylated. 
About 3.500 of 7.354 CpG sites which shown different AVG Beta levels 
ranging from 50 to 80% of DNA methylation.    
 
Generally, in all of studies, controls with terminal birth and adequate 
intrauterine growth display a high methylation status followed by preterm and 
SGA controls and lastly by affected subjects. 
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Figure 17: DNA methylation trends of cases and ctrls categorized by gestational age, 
intrauterine growth and thyroid function. About 4.000 of 19.252 CpG island sites, which 
ranging from 5 to 20% of AVG Beta values shown different methylation levels. 
Approximately 3.500 of 7.354 Non-CpG island sites that range from 50 to 80% of AVG 
Beta values shown different have different methylation status. 
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6.4.2 Comparison of mean-AVGbeta values  
 
The study of the global methylation status about their AVG Beta levels confirmed 
these different trends. 
 
Analysis of autosomes:  are shown in histograms reported below (figure 18), we 
found that the mean of AVG Beta values was statistically significant different 
when we compared: 
 CH-VPB and CH-PB with TB controls, both for CpG island and non-CpG 
island sites.   
 CH-SGA with AGA controls for CpG island sites.  
 SH than OH cases, PB and TB controls for CpG island sites and SH with TB 
controls for non-CpG island sites. 
 
 
 
 
85 
 
 
 
Figure 18: Comparison of autosome mean-AVG Beta values. Gestational age approach: 
significant differences of global methylation were found between CH-VPB and C-TB both 
for CpG island and Non-CpG island sites. Intrauterine growth approach: p<0.05 of CpG 
island sites between CH-SGA and C-AGA. Thyroid function approach: significant 
differences of CpG island sites between SH and OH, C-PB and C-TB and about Non-CpG 
island among SH and C-TB. 
 
 
Sexual chromosome: the analysis of Chr-X methylation (figure 19), revealed 
significant differences between: 
 VPB female and male with TB ctrls for CpG island and VPB female with 
TB ctrls. 
 SGA and AGA female with AGA ctrls for CpG island and AGA female 
with TB ctrls for non-CpG island sites. 
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 SH female and male with TB ctrls for CpG island and VPB female with 
TB ctrls. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Comparison of Chr X mean-AVG Beta values. Gestational age approach: 
significant  differences of global methylation were found between CH-VPB female and 
male and C-TB for CpG island sites and CH-VPB female vs C-TB for Non-CpG island sites. 
Intrauterine growth approach: p<0.05 of CpG island sites between both CH-SGA female 
and male and C-AGA. p<0.05 of Non-CpG island sites among CH-SGA female vs C-AGA. 
87 
 
Thyroid function approach: significant differences of CpG island sites between female 
and male SH and C-TB and about Non-CpG island among SH female and C-TB. 
 
6.4.3 Summary of global methylation analysis results 
 
The results of the global methylation analysis have shown that affected subjects 
with prematurity associated with CH have a different methylation status than 
healthy controls. In facts, the clustering of subjects revealed that only child with 
SGA and comparable levels of TSH localized vey close. Also, twin pairs discordant 
for CH clustered together in presence of SH while twin with OH are localized far 
form his brother. These results suggested that TSH levels may be correlated with 
methylome status even in the presence of high genetic similarity. The 
comparison of the DNA methylation trends and the mean values of AVG Beta 
highlighted that cases are hypomethylated than controls with term birth. 
Generally, these differences are statistically significant when compared cases 
with severe or not prematurity and intrauterine growth delay than C-TB for both 
CpG island and Non-CpG island for autosomes and X-chromosome. The analysis 
of thyroid function approach indicates that CH with subclinical hypothyroidism 
has a significant hypomethylation status than controls. This finding could be 
explained by clinical data of these patients. As listed in table, the SH group has 
average levels of gestational age and birth weight significantly lower than others. 
This suggests that such factors are associated and justifying the low levels of DNA 
methylation. Based on these early results, it seems that the premature birth 
associated with CH, especially in the presence of intrauterine growth restriction 
is related with global hypomethylation. The direct link between TSH levels and 
hypomethylation remain unclear but the analysis of clustering and the low but 
not significant levels of methylation of OH-cases suggest its possible 
involvement.  
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6.5 GENE-SPECIFIC DNA METHYLATION ANALYSIS 
 
6.5.1 Selection of Differentially Methylated Genes (DMGs) 
 
Through the gene-specific DNA methylation analysis by FDR<0.01, Differential  
Score< 0.05 and AVG delta Beta> 0.05 we selected the sets of DMGs that are 
hypomethylated in affected children than term and AGA controls. 
As shown in the histograms and table below, approximately 90-96% of DMGs are 
hypomethylated in cases with CH (figure 20). Interestingly, about 70% of these 
genes are represented by Non-CpG island sites. On the contrary the comparison 
with preterm controls doesn’t show a significant number of DMGs.  
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Figure 20: Graphical representation of the number of DMGs in cases versus controls of 
autosomes. In dark blue are display hypomethylated genes in cases than C-TB and C-
AGA, and in a light blue the hypomethylated genes in cases than C-PB and C-SGA. In the 
table are reported the total of DMGs selected, the number of hypomethylated genes 
and how many of them are members of CpG island or Non-CpG island. In parentheses 
are reported the percentages of these data.  
 
Regarding on the analysis of sexual chromosome we selected (figure 21): 
 Female: a total of 116 DMGs, that are almost totally hypomethylated in 
CH-VPB than term controls. The majorities of these genes are 
represented by CpG island sites. 
 Male: we found a total of 373 DMGs, which the 94-98% is 
hypomethylated in CH-VPB then term controls.  
 
 
Figure 21: Graphical representation of the number of DMGs in cases versus controls of 
Chr-X. In dark blue are display hypomethylated genes in cases than C-TB and C-AGA, and 
in a light blue the hypomethylated genes in cases than C-PB and C-SGA both for female 
and male. In the table are reported the total of DMGs selected, the number of 
hypomethylated genes and how many of them are members of CpG island or Non-CpG 
island. In parentheses are reported the percentages of these data.  
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6.5.2 Selection of “common genes”  
 
Through a differential score plot comparison of all DMGs resulting from the three 
studies, we selected a total of 154 of autosomes. In addition we found 79 DMGs 
in common between male and female VPB cases (figure 22). We then clustered 
all CH-patients according to the 154 DMGs to find which factors are related to 
the gene-specific hypomethylation.  
As reported in the figure 23, we find that CH-children with comparable 
gestational age and low weight at birth clustered together. On the contrary, 
affected infants with low gestational age and proper weight at birth are spread 
far away. The most significant results are those concerning the analysis of 
concordant and discordant twin pairs for CH. In fact, both of twin pairs with low 
birth weight clustered together, unlike the siblings with normal birth weight. 
These results confirm that gene-specific hypomethylation is associated to 
prematurity with low birth weight. Thyroid defects seem to be, therefore, a 
secondary effect from this condition.  
 
 
 
Figure 22: Venn diagram having the number of DMGs of autosomes and of Chr-X that 
are in common between CH subgroups.  
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Figure 23: schematic representation of cluster of CH-patients according to the 154 
DMGs.  
 
 
 
6.5.3 Features of differentially methylated loci 
 
In table 8 are reported the full list and the details of the 154 DMGs resulted by 
the gene-specific methylation analysis. Reflecting the global DNA methylation 
analysis, the 75% of these genes were represented by CpG sites located into non-
coding regions, while the remained 25% was characterized by CpG island sites 
situated into promoters of target genes. Several works reported the association 
of DNA hypomethylation and genomic instability. This condition is known to be 
related to cancer predisposition, adverse pregnancy outcomes and birth defects. 
Then we conducted a topological analysis to study the distribution of 
chromosomal epigenetic changes related to CH onset and fetal development. In 
this regard, using the list of sites previously identified as CpG significant variables 
in both the preterm than in intrauterine growth restriction associated with CH it 
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was calculated distribution at the chromosomal level. In particular, for each 
chromosome, the results for the frequencies have been reported as the 
percentage ratio between the numbers of CpG sites differently methylated and 
the number of the CpG sites represented by Illumina BeadChip.                          
The epigenetic changes in Non-CpG island sites are found to have a significantly 
greater rate in chromosomes 1, 2, 3, 6, 7 and 17 compared to that expected for 
randomly selected genes (figure 24). Instead, CpG island sites seem to be 
distributed homogeneously within the genome.                                                                     
Finally, through GeneImprint public database we search which DMGs are 
imprinted or not (http://igc.otago.ac.nz and http://www.geneimprint.com). 
Three genes are known to be dependent of parent-of-origin (DLK1, GNAS and 
KCNQ1) and two are predicted to be imprinted (HOXB2 and SLC38A4) (Table 8).   
The interpretation of DNA methylation of imprinted control regions (ICRs) of 
these genes is more difficult that non-imprinted genes. For example, this 
complexity can be illustrated by the data of GNAS genes for which 30 probes 
across 3 promoter regions of 3 alternative transcripts (NESP55, GNASXL and exon 
1A of GNAS), were present on the Infinium array (figure 25). 8/30 probes are 
differentially methylated and have AVGΔβ values between 10 to 20% (figure 26). 
The interpretation of the methylation data for these genes depends on the 
number of probes that show significant differences and the percentage of loss or 
acquisition of DNA methylation. For these reasons it is necessary to validate 
these findings with other methods. 
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Symbol Product Chormosome CpG island AVGΔβ Imprinted Allele
A2M alpha-2-macroglobulin precursor 12 N -7%
ABCB1 ATP-binding cassette sub-family B member 1 7 N -5%
ACF apobec-1 complementation factor isoform 1 10 N -6%
ADAMTSL5 thrombospondin; type I; domain containing 6 19 N -8%
ADH1C class I alcohol dehydrogenase; gamma subunit 4 N -7%
ADH7 class IV alcohol dehydrogenase 7 mu or sigma subunit 4 N -7%
ADIPOQ adiponectin precursor 3 N -6%
ALDOB aldolase B, fructose-bisphosphate 9 N 12%
APOBEC1 apolipoprotein B mRNA editing enzyme isoform 2 12 N -5%
APOBEC4 apolipoprotein B mRNA editing enzyme 1 N -8%
APOD apolipoprotein D precursor 3 N -6%
ATP5A1 ATP synthase; H+ transporting; mitochondrial F1 complex 18 N -6%
BMP10 bone morphogenetic protein 10 preproprotein 2 N -6%
BMP4 bone morphogenetic protein 4 preproprotein 14 N -6%
CALCA calcitonin isoform CALCA preproprotein 11 Y -6%
CCL5 small inducible cytokine A5 precursor 17 N -5%
CER1 cerberus 1 homolog 21 N -5%
CHIA eosinophil chemotactic cytokine 1 N -8%
CIR CBF1 interacting corepressor isoform 2 2 N -5%
CLEC12A myeloid inhibitory C-type lectin-like receptor isoform alpha 12 N -7%
CPA5 carboxypeptidase A5 7 N -6%
CRYM crystallin; mu isoform 1 16 N -6%
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 15 N -7%
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 7 N -7%
DHRS4 dehydrogenase/reductase (SDR family) member 4 14 Y -21%
DHRS4L2 dehydrogenase/reductase (SDR family) member 4 like 2 14 N -5%
DLK1 delta-like 1 homolog isoform 2 14 Y -6% Y paternal
EPS8L1 epidermal growth factor receptor 8-like protein 19 N -19%
ESR1 estrogen receptor 1 6 Y -12%
FABP1  fatty acid binding protein 1, liver 2 N -5%
FABP2  fatty acid binding protein 2, liver 4 N -6%
FABP4  fatty acid binding protein 4, liver 8 N -5%
FCRL4 Fc receptor-like 4 1 N -6%
FGF7 fibroblast growth factor 7 precursor 15 N -6%
FORL2 folate receptor 2 17 N -7%
GCG glucagon preproprotein 2 N -7%
GDF15 growth differentiation factor 15 19 Y -7%
GLI2 GLI-Kruppel family member GLI2 isoform delta 2 N -8%
GNA11 guanine nucleotide binding protein; alpha 11 (Gq class) 19 Y -15%
GNAS guanine nucleotide binding protein; alpha stimulating activity polypeptide 1 isoform a20 Y -25% Y isoform-dip
GRM5 glutamate receptor; metabotropic 5 precursor 11 N -7%
GRM8  glutamate receptor, metabotropic 8 7 N -5%
GSTA5 glutathione transferase A5 6 N -6%
GSTM1 glutathione S-transferase M1 isoform 1 1 Y -10%
GSTM5 glutathione S-transferase M5 1 Y -7%
GSTT1 glutathione S-transferase theta 1 22 Y -6%
GUCA1C guanylate cyclase activator 1C 3 N -9%
GUCY2C guanylate cyclase 2C (heat stable enterotoxin receptor) 12 N -5%
HLA-C major histocompatibility complex, class I, C 6 N -7%
HLA-DQB1 major histocompatibility complex; class II; DQ beta 1 precursor 6 N -7%
HLA-DQB2 major histocompatibility complex; class II; DQ beta 2 6 N -12%
HOXB2 homeo box B2 17 N -5% P maternal
HOXB5 homeo box B5 17 N -5%
HOXB6 homeo box B6 isoform 1 17 N -7%
HRH1 histamine receptor H1 3 N -8%
HTR5A 5-hydroxytryptamine (serotonin) receptor 5A 7 N -8%
HTR1F 5-hydroxytryptamine (serotonin) receptor 1F 3 N -6%
IFNA16 interferon, alpha 16 9 Y -7%
IL10  interleukin 10 1 N -6%
IL5  interleukin 5 11 N -8%
KCNAB3 potassium voltage-gated channel; shaker-related subfamily 17 Y -12%
KCNE2 potassium voltage-gated channel; Isk-related family 21 Y -7%
KCNJ16 potassium inwardly-rectifying channel J16 17 N -6%
KCNQ1 potassium voltage-gated channel; KQT-like subfamily 11 Y -9% Y maternal
KCNRG potassium channel regulator isoform 1 13 Y -7%
KCTD1 potassium channel tetramerisation domain containing 1 18 N -6%
KCTD2 potassium channel tetramerisation domain containing 2 17 N -7%
KRTAP19-2 keratin associated protein 19-2 21 N -6%
KRTAP21-1 keratin associated protein 21-1 21 N -5%
KRTAP21-2 keratin associated protein 21-2 21 N -7%
KRTAP4-4 keratin associated protein 4.4 17 N -9%
KRTAP9-4 keratin associated protein 9-4 17 N -5%
LCE2B late cornified envelope 2B 1 N -5%
LDHC lactate dehydrogenase C 11 N -11%
LTB4R leukotriene B4 receptor 14 N -9%
MAPK9 mitogen-activated protein kinase 9 isoform 1 5 N -6%  
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MASP1 mannan-binding lectin serine protease 1 isoform 1 precursor 3 N -6%
MBNL2 muscleblind-like 2 isoform 1 13 N -5%
MGMT O-6-methylguanine-DNA methyltransferase 10 N -6%
MGP matrix Gla protein 12 N -7%
MMP10 matrix metalloproteinase 10 preproprotein 11 Y -6%
MMP14 matrix metalloproteinase 14 preproprotein 14 Y -5%
MMP21 matrix metalloproteinase 21 preproprotein 10 N -6%
MSX1 msh homeo box homolog 1 5 Y -6%
MTHFD2 methylene tetrahydrofolate dehydrogenase 2 precursor 11 Y -10%
MYH3 myosin; heavy polypeptide 3; skeletal muscle; embryonic 17 N -7%
NALP12 PYRIN-containing APAF1-like protein 7 isoform 1 19 N -7%
NOS3 nitric oxide synthase 3 (endothelial cell) 7 N -6%
NUDT12 nudix -type motif 12 5 N -6%
PAN3 PABP1-dependent poly A-specific ribonuclease subunit PAN3 13 N -5%
PARG poly (ADP-ribose) glycohydrolase 10 N -5%
PARVB parvin; beta isoform b 22 Y -7%
PDE1A phosphodiesterase 1A; calmodulin-dependent isoform 2 2 N -7%
PDE3B phosphodiesterase 3B; cGMP-inhibited 11 Y -6%
PDE4D cAMP-specific phosphodiesterase 4D 5 Y -6%
PEBP1 phosphatidylethanolamine binding protein 1 12 N -6%
PHC2 polyhomeotic 2-like isoform a 1 N -6%
PLD4 phospholipase D family; member 4 14 Y -5%
PLG plasminogen 6 N -7%
PRL prolactin 6 N -8%
PSCA prostate stem cell antigen 8 Y -17%
PSMD5 proteasome 26S non-ATPase subunit 5 9 Y -7%
PTH parathyroid hormone preproprotein 11 N -6%
PTMA prothymosin; alpha (gene sequence 28) 2 N -6%
PTPN3 protein tyrosine phosphatase; non-receptor type 3 9 N -6%
RALBP1 ralA binding protein 1 18 Y -5%
RARRES2 retinoic acid receptor responder (tazarotene induced) 2 7 Y -9%
RDH12 retinol dehydrogenase 12 (all-trans and 9-cis) 14 Y -5%
REG1B regenerating islet-derived 1 beta precursor 2 N -5%
RPL4 ribosomal protein L4 15 N -6%
RRH peropsin 4 N -6%
RUNX2 runt-related transcription factor 2 isoform b 6 N -6%
SELE selectin E precursor 1 Y -6%
SLC10A2 solute carrier family 10; member 2 13 Y -6%
SLC13A1 solute carrier family 13; member 1 7 Y -5%
SLC16A4 solute carrier family 16; member 4 1 N -7%
SLC17A2 solute carrier family 17 (sodium phosphate); member 2 6 N -6%
SLC17A4 solute carrier family 17 (sodium phosphate); member 4 6 N -5%
SLC25A15 solute carrier family 25; member 15 13 N -5%
SLC25A20 carnitine/acylcarnitine translocase 3 N -6%
SLC2A9 solute carrier family 2; member 9 protein isoform 1 4 Y -5%
SLC30A8 solute carrier family 30 member 8 8 Y -5%
SLC38A4 solute carrier family 38; member 4 15 Y -8% P UN
SLC39A12 solute carrier family 39 (zinc transporter); member 12 10 Y -6%
SLC4A5 sodium bicarbonate transporter 4 isoform a 2 N -7%
SLC4A7 solute carrier family 4; sodium bicarbonate cotransporter 3 N -6%
SLC5A10 solute carrier family 5; member 10 17 N -5%
SLC5A4 solute carrier family 5 (low affinity glucose cotransporter) 22 N -5%
SMURF SMAD specific E3 ubiquitin protein ligase 1 7 N -6%
SOX6 SRY (sex determining region Y)-box 6 11 N -6%
SRD5A2 3-oxo-5 alpha-steroid 4-dehydrogenase 2 2 Y -7%
STK38 serine/threonine kinase 38 6 N -6%
SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-preferring 11 N -9%
SULT1A2 sulfotransferase family, cytosolic, 2A, phenol-preferring 16 N -12%
SUMO2 small ubiquitin-like modifier 2 isoform a precursor 17 N -7%
SUMO3 small ubiquitin-like modifier protein 3 17 N -5%
SUSD1 sushi domain containing 1 9 Y -6%
TAS2R1 taste receptor T2R1 5 N -7%
TAS2R10 taste receptor; type 2; member 10 12 N -6%
TDG thymine-DNA glycosylase isoform 2 12 Y -8%
TFDP2 transcription factor Dp-2 (E2F dimerization partner 2) 3 N -5%
TG thyroglobulin 8 Y -6%
TGIF TG-interacting factor isoform c 18 N -6%
TGM3 transglutaminase 3 precursor 20 N -10%
THOP1 thimet oligopeptidase 1 19 N -5%
THRSP thyroid hormone-responsive protein 11 N -6%
THSD4 thrombospondin, type I, domain containing 4 15 N -5%
TIN tubulointerstitial nephritis antigen-like 1 1 N -6%
TMPRSS11D transmembrane protease; serine 11D 4 N -9%
TREML2 triggering receptor expressed on myeloid cells-like 2 6 N -6%
TRIM16 tripartite motif-containing 16 17 N -8%
TRIP6 thyroid hormone receptor interactor 6 7 N -5%
UCN2 urocortin 2 3 N -6%
UGT2A1 UDP glycosyltransferase 2 family; polypeptide A1 4 N -6%
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Table 8: general features of the 154 DMGs: symbols, products, chromosomes and CpG 
sites location are reported. The hypomethylated status of each gene is display as a 
percentage of the differences between cases and controls (AVGΔβ). In the last two 
columns are the genes subjected to imprinting (Y) or predicted (P), and the type of 
inheritance as maternal, paternal, isoform-dependent or unknown (UN). 
 
 
Figure 24: Chromosomes localization of the 154 DMGs. Data are reported as a number 
of DMGs for each chromosome and then we compared the % of these genes with total 
genes represented by the Illumina array.  Chromosomes 1, 2, 3, 6, 7 and 17 shown a 
higher frequency of CpG sites then expected (*). 
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Figure 25: GNAS locus has a highly complex imprinted expression pattern. It gives rise to 
maternally, paternally, and biallelically expressed transcripts that are derived from four 
alternative promoters and 5' exons. The GNAS locus is imprinted and encodes 5 main 
transcripts: Gs-α, XLAS, NESP55, A/B transcript, antisense GNAS transcript. Some 
transcripts contain a differentially methylated region (DMR) at their 5' exons, and this 
DMR is commonly found in imprinted genes and correlates with transcript expression. 
An antisense transcript exists, and this antisense transcript and one of the transcripts 
are paternally expressed, produce noncoding RNAs, and may regulate imprinting in this 
region. In addition, one of the transcripts contains a second overlapping ORF, which 
encodes a structurally unrelated protein. 
 
 
 
 
Figure 26: GNAS complex on Illumina’s array. 30 probes cover the differentially 
methylated regions (DMRs) of the five alternative transcripts. 8 to 30 probes are 
differentially methylated and have AVGΔβ values between 10 to 20%.  
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6.6 CATEGORIZATION OF DIFFERENTIALLY METHYLATED 
GENES 
 
6.6.1 Gene Ontology Enrichment analysis  
 
The analysis with DAVID conducted on this restricted list of 154 DMGs has 
allowed characterizing with higher resolution the biological processes involved in 
cellular functions during fetal and thyroid development. Thus, we tested whether 
specific GO terms of the genes associated with one or more DMGs were enriched 
when compared to the GO distribution of all the 154 autosomal genes associated 
with CpG sites present on the array that we analyzed.  
Biological processes such as regulation and response to hormone stimulus, post-
embryonic development, regulation of retinoic metabolism, metabolism of 
vitamins and sulfur metabolism are found to be regulated at the epigenetic level 
(figure 27).  
The inclusion of these specific processes within the top ten most significant gene 
set overlaps provided evidence of strong biological relevance of the differentially 
methylated genes to fetal development and thyroid function. 
We then analyzed the DMGs with KEEG pathway search database to find which 
signal pathways are involved in these epigenetics changes. Interestingly, 
pathways implicated in the autoimmune thyroid disease, metabolism of 
xenobiotic and in metabolism of retinol are found to be significantly enriched 
(table 9).  
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Figure 27: Gene Ontology Enrichment analysis of 154 DMGs by DAVID database. On the 
horizontal axis are reported the number of genes and in the vertical axes the biological 
processes that are enriched.   
 
 
PATHWAY P VALUE GENES
Metabolism of xenobiotic P450 9.4 E-4 UGT2A1, ADH7, ALDH3B2, GSTA5, GSTM1, GSTM5, GSTT1
Autoimmune thyroid disease 6.3 E-3 IFNA16, IL10, IL5, HLA-C, HLA-DQBA, TG
Neuroactive ligand-receptor interaction 7.3 E-3 HTRA1F, HTR5A, MAS1, GRM5, GRM8, GHRHR, HRH2, LTB4R, PLG, PTAFR, PRSS3
Glycolysis/gluconeogenesis 1.2 E-3 ADH7, ALDH3B2, ALDOB, GALB, LDHC
PPAR signalling pathway 5.7 E-2 ACSL5, ADIPOQ, FABP1, FABP2, FABP4
Calcium signalling pathway 8.2 E-2 HTR5A, GNAS, GRM5, GNA11, HRH2, NOS3, PDE1A, PTAFR
Retinol metabolism 8.8 E-2 UGT2A1, ADH7, DHRS4L2, RDH12
KEGG-Pathway Database
 
Table 9: Pathway search analysis of DMGs by KEEG Database. In this table are display 
the biological pathway enriched, the p-value and the lists of genes involved. 
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6.6.2 Selection of the “top genes” 
 
Finally, we selected a short list of genes of particular interests for further studies 
since it’s involved in fetal development and action of thyroid hormones at 
peripheral level:  
 
BMP10, BMP4 and SMURF: BMPs proteins belong to the TGF- pathway family 
and are multifunctional growth factors involved in many aspects of tissue 
development and morphogenesis [Mandel et al., 2010]. The important 
functioning of BMP signals in physiology is emphasized by the multitude of roles 
for dysregulated BMP signalling in pathological processes. Especially cancerous 
disease often involves alterations of the BMP signalling system. Absence of BMP 
signalling is, for instance, an important factor in the progression of colon cancer 
[Samavarchi-Tehrani et al., 2010] and conversely overactivation of BMP signalling 
following reflux-induced esophagitis provokes Barrett's esophagus and is thus 
instrumental in the development of adenocarcinoma in the proximal portion of 
the gastrointestinal tract [Barros et al., 2008]. Interestingly, thyroid hormones 
induce the local BMP expression to stimulate the cell metabolism and growth 
[Milano et al., 2007]. 
 
DLK1, CIR1: Dlk1 has evoked considerable interest because in mammals it is a 
paternally expressed imprinted gene that is epigenetically regulated, and 
defective imprinting of Dlk1 results in developmental abnormalities [Begemann 
et al., 2012]. The developmental mechanisms leading to these abnormalities are 
unknown and in particular it is unclear the extent to which this protein has the 
capability of regulating Notch signalling in vivo, because it lacks an essential 
extracellular DSL domain common to all known Notch ligands. Both its lack of a 
DSL-domain and its short intracellular domain suggest therefore that DLK1 would 
not be able to function as a Notch ligand. However, as an inverse correlation 
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between Dlk1 levels and Notch activity have been observed in cultured cells, it is 
possible that DLK1 could be a receptor antagonist [Sánchez-Solana et al., 2011]. 
Corepressor interacting with RBPJ (CIR1) may modulate splice site selection 
during alternative splicing of pre-mRNAs. CIR1 regulates transcription and acts as 
a corepressor for RBPJ and play a central role in Notch signaling. Recruits RBPJ to 
the Sin3-histone deacetylase complex (HDAC) and is required for RBPJ-mediated 
repression of transcription [Hsieh et al., 1999].  
The notch signaling pathway is important for cell-cell communication, which 
involves gene regulation mechanisms that control multiple cell differentiation 
processes during embryonic and adult life. Notch signaling is dysregulated in 
many cancers, and faulty notch signaling is implicated in many diseases including 
T-ALL (T-cell acute lymphoblastic leukemia), CADASIL (Cerebral Autosomal 
Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy), MS 
(Multiple Sclerosis), Tetralogy of Fallot, Alagille syndrome, and many other 
disease states [Mead et al., 2012]. Recently a possible role for Notch signal in 
thyroid development has been proposed [Ferretti et al, 2008; Geers et al., 2011]. 
 
GSTA5, GSTM1, GSTT1, and GSTM5: Genes encoded for glutathione-S-
transferases (GSTs) are strongly hypomethylated in affected infants. It’s well 
known that oxidative stress is closely related to fetal stress and adverse 
pregnancy outcomes [257]. Level of expression of GSTs is a crucial factor in 
determining the sensitivity of cells to a broad spectrum of carcinogens, 
antitumor drugs, environmental pollutants, and products of oxidative stress. 
Some reports demonstrated the association between oxidative stress and 
hypothyroidism [258]. Hypothyroid rats shown elevated plasma levels of 
homocysteine, nitric oxygen (NO) metabolites and oxidized glutathione/reduced 
glutathione (GSSG/GSH) ratio due to a selenium deficiency and GSTs expression.  
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Folic acid supplementation combined with L-tiroxine therapy ameliorating not 
only the thyroid state but also the antioxidant status. It’s also reported that 
thyroid hormone (THs) have a strong impact on the antioxidant system.  
Physiological levels of THs repress the expression of these genes and protect cells 
to the adverse effects of oxidative stress [259]. 
 
ADH7, DHRS4L2, and DHR12: these hydrolytic enzymes are involved in the 
homeostasis of retinoic acid. The biosynthesis of active forms of retinoids are 
critical for many physiological processes, including embryonic development, 
reproduction, postnatal growth, differentiation and maintenance of various 
epithelia, immune responses, and vision and could activate gene expression 
through a thyroid hormone response element [260]. 
Retinol is converted by alcohol dehydrogenase to retinaldehyde, which is 
subsequently converted by retinaldehyde dehydrogenase to all-trans retinoic 
acid (ATRA). ATRA undergoes isomerization in hepatic microsomes to 13-
cisretinoic acid (RA) and 9-cis RA, depending on the levels of converting enzymes 
and cellular retinol binding protein. These retinoids can influence expression of 
many genes through nuclear receptors [retinoic acid receptor (RAR) and retinoid 
X receptor (RXR)]. It was reported that that a synthetic RXR-selective retinoid, 
LG1069, can cause central hypothyroidism in patients through a profound 
suppression of serum TSH levels [261].  
 
PDE4D, PDE3B: Cyclic nucleotide phosphodiesterases (PDEs) catalyze the 
hydrolytic inactivation of the common intracellular second messenger’s cyclic 
adenosine (cAMP). Thus these enzymes play a critical role in the regulation of a 
wide range of physiological processes such as the TSH regulation and the 
negative feedback of thyroid hormone actions [262]. PDE4D is expressed in the 
thyroid and its overexpression is believed to counteract the constitutive 
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activation of cAMP pathway induced by TSHR or Gsa gain-of-function mutations 
in thyroid adenomas (Persani et al., JCEM 2000). 
 
SULT1A1, SULT1A2: Sulfation, catalyzed by sulfotransferase enzymes (SULTs), is 
an important pathway of thyroid hormone metabolism by which T(4) is 
irreversibly converted to inactive reverse T(3) rather than active T(3) [263]. 
Impairment in SULT1A1 and SULT1A2 activity have a mild effects and thyroid 
status but have a strong effect in liver, brain and kidneys in animal model [264]. 
 
IFNA16, HLA-C and HLA-DQBA: Autoimmune thyroid disease (AITD) causes 
cellular damage and alters thyroid gland function by humoral and cell-mediated 
mechanisms. Cellular damage occurs when sensitized T-lymphocytes and/or 
autoantibodies bind to thyroid cell membranes causing cell lysis and 
inflammatory reactions. Anti-thyroid antibodies have been implicated in adverse 
pregnancy outcomes [265] and the onset of congenital hypothyroidism [266]. 
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6.7 Analysis of MTHFR polymorphisms 
 
In this paragraph the genetic analysis of MTHFR is reported. Although several 
factors are known to be related to global and gene-specific hypomethylation, 
polymorphisms in this gene are responsible to maternal folate deficiency and 
fetal hypomethylation. 
Methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-
methylenetetrahydrofolate (5,10-CH2-THF) to 5-methyltetrahydrofolate (5-
MeTHF), a co-substrate for homocysteine remethylation to methionine. Genetic 
variations in this gene are associated with MTHFR are positively correlated with 
lower serum and red blood cell folate concentrations [267]. 
Several studies reported that maternal folate deficiency during pregnancy 
influences the susceptibility to occlusive vascular disease, neural tube defects, 
colon cancer and acute leukemia. Exactly how MTHFR mutations can cause 
pregnancy complications is unknown; a logical hypothesis is that endothelial 
damage from hyperhomocysteinemia leads to venous thromboembolism and 
placental insufficiency [268]. 
Several non-synonymous single nucleotide polymorphisms (SNPs) are present in 
the coding region of the gene including positions 677 and 1298. The most studied 
SNP is the 677 C>T substitution that results in an amino acid change from alanine 
to valine at codon. The MTHFR 1298A>C polymorphism results in a substitution 
of glutamate with alanine. MTHFR enzyme activity is reduced by 35% among the 
677C/T carriers and by 50% to 70% among 677T/T carriers. The function of 
polymorphism 1298A>C has not been consistently demonstrated; however 
carriers of the heterozygous genotypes (677CT/1298AC) show MTHFR activity 
similar to that in MTHFR677T/T carriers. The reduction in MTHFR activity increases 
homocysteine levels and in turn reduces the availability of the DNA methyl 
groups [270]. 
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To date, nine maternal blood samples were analysed; six of them are parents of 
concordant and discordant twin pairs and three are mothers of affected only 
child. Genomic DNA from mothers was extracted and DNA ampliﬁcation and 
genotyping of MTHFR 677 C>T and 1298 A>C were performed by polymerase 
chain reaction (PCR-RFLP) according to the protocol suggested by Chen and 
Weisberg [271]. 
As shown in table 10, two of four mothers of discordant twin pairs carry the 
homozygous variant MTHFR677T/T, while the others have the heterozygous 
polymorphisms MTHFR677C/T and MTHFR1298A/C, respectively.  
These single heterozygous genotypes are also found in four mothers of 
concordant twins and only child. One parents of CH-only child bring a double 
heterozygous polymorphisms (MTHFR677C/T, 1298A/C).  
Mothers with the MTHFR677T/T genotypes are those whose affected twins are 
born small for gestational age. Single MTHFR677C/T polymorphisms are found in 
mothers of one AGA discordant twin pairs and two SGA only children. 
MTHFR1298A/C variants are found in mothers of AGA discordant twins, SGA/AGA 
concordant twins and in SGA only child. The MTHFR677C/T, 1298A/C genotype is 
carried by parents of SGA only-child.  
Although these data have to be extended and validated, the presence of these 
genetic variants appears invariably associated with intrauterine growth delay. 
Maternal folate deficiency caused by MTHFR deficiency leads to a shortage of 
methyl-donors and as a consequence to the hypomethylation status. The 
genomic instability and the altered regulation of certain factors may have 
potentially affected the pregnancy outcome and fetal development.  
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Table 10: MTHFR genotyping. Nine mothers are collected and analyzed for the presence 
of 677 C/T and 1298 A/C polymorphisms. Kinship and clinical data of sons are reported: 
gestational age (GA), birth weight (BW), TSH values and the presence (y) or absence (n) 
of intrauterine growth delay (SGA).  (*) marks the heterozygous state while (**) the 
homozygous variant. 
 
 
6.6.3 Summary of results of gene-specific methylation analysis 
 
The gene-specific methylation analysis confirmed the scenario of the global 
methylation study. Almost all of DMGs of autosomes are  less methylated in CH 
patients than in term and AGA controls, and about 70% of DMGs are located into 
Non-CpG island sites. To find which factors are directly related to the 
hypomethylation, through a scatter plot and association analyses we selected a 
subsets of 154 DMGs that are in common between the subgroups of cases. By a 
sample clustering we find that the gestational age and the birth weight are the 
principal indicators of this methylome aberration. In fact, affected SGA infants 
with low BW are clustered together while the others are distributed randomly. 
No direct association on TSH levels was found. These data are confirmed to the 
fact that twins concordant and discordant for IC are distributed according to 
birth weight; twin pairs with comparable weight are grouped together; on the 
contrary, twins with different weight are not clustered together. This finding 
suggests that the degree of prematurity and intrauterine growth is directly linked 
to the DNA hypomethylation and the increased predisposition to CH onset could 
represent a secondary event or a strongly associated co-variate. Interestingly, 
the 75% of the hypo-DMGs are localized into the Non-CpG island regions and for 
Mothers CH-infants GA (wks) BW (g) TSH (U/ml) SGA MTHFR 677C/T MTHFR 1298A/C
M1 Discordant-TP 35.1 1830/2043 13.55/ 1.13 y/n T/T** A/A
M2 Discordant-TP 25.1 680/843 20/1.92 n/n C/T* A/A
M3 Discordant-TP 30.4 2300/2630 18.23/2.24 n/n C/C A/C*
M4 Discordant-TP 31 930/1122 11.1/1.35 y/n T/T** A/A
M5 Concordant-TP 35 1330/2150 19.6/13.5 y/n C/C A/C*
M6 Concordant-TP 36.5 2650/2300 262.8/150 n/n C/C A/A
M7 Only child 32,5 1330 13,27 y C/T* A/A
M8 Only child 33 1262 125 y C/T* A/C*
M9 Only child 37 2030 15 y C/C A/C*
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the 25% into a promoter CpG island. About the chromosomes distribution of the 
154 DMGs, non-CpG island sites showed an overestimation than the expected 
frequencies in chromosomes 1, 2, 3, 6, 7 and 17. By GeneImprint software, we 
found 5 genes known or predicted to be imprinted but the interpretation of their 
methylation status and the biological significance has to be further validated. 
Then we analyzed the presence of MTHFR polymorphisms in nine mothers and 
we found that two of them are homozygous and three are heterozygous for 
677C/T variants. Two mothers are heterozygous for the 1298A/C variants and 
one of them have a double heterozygous genotype. In the end, by the Gene 
Ontology and KEEG Pathway database we have found that several genes belong 
to the biological processes involved in fetal development and maintenance the 
homeostasis of hormone levels. We then selected a set a top genes that are 
particularly interesting for further studies. 
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CHAPTER VII 
6. DISCUSSION 
 
The etiophatogenesis of congenital hypothyroidism (CH) is still poorly 
understood. Studies in animal model and human screening programs have been 
demonstrated that CH is a multigenic [Amendola et al. 2004; Trueba et al., 2005] 
and a multifactorial [Olivieri et al., 1999; Medda et al., 2005] disease. Although 
the genetic component is still widely studied, the occurrences of mutations in 
genes known to be involved in the development of the disease have been 
observed only in a small proportion (15-20%) of the CH patients [Olivieri et al., 
2009].  
During pregnancy, the fetus is exposed to a plethora of endocrine and metabolic 
stimuli that enable it to a proper growth [Mitskevich et al., 1990]. It has been 
hypothesized that environment affects maternal and fetal metabolism which 
results in an increased risk in birth thyroid defects [Liu et al., 2009]. However, the 
etiological role of specific environmental risk factors is far to be understood. 
Recent works published by Olivieri et al., indicates that the risk of CH onset 
depends on maternal and gestational factors. Iodine deficiency and maternal 
diseases as diabetes play a role in the development of CH [Olivieri et al., 2007]. 
The multifactorial origin of CH was also supported by results obtained in the 
study on CH twins recorded in the INRICH between 1989 and 2000. This study 
showed that, despite a low concordance rate (4.3%) for permanent CH observed 
among twins at birth, a high recurrence risk for the disease was present among 
siblings of CH cases. Moreover, given the high discordance rate for CH their data 
suggest the importance of environmental risk factors in the etiology of CH and a 
possible role of competitive conditions regarding metabolic factors in utero 
[Medda et al., 2005].  
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Works from Radetti and colleagues, conducted in groups of children with term 
and preterm birth reported interestingly but non-conclusive results. They 
examined a group of children of the same gestational age, they found an 
increased prevalence of thyroid dysfunction in those born SGA and identified in 
the shorter length at birth the cause for the thyroid alteration [Radetti et al., 
2004].  
In a further work, conducted in a large group of patients born either preterm or 
at term, children born prematurely, independently from their birth weight or 
length frequently presented mild dysfunctions of the hypothalamus-pituitary-
thyroid axis later in life [Radetti et al., 2007].  
These data are in agreement with the results of Cianfarani et al., who showed 
that SGA children born at term, while having higher TSH values, compared with 
controls, all had TSH levels less than 10 U/ml [Cianfarani et al., 2003]. Even if 
the association between intrauterine environment, premature birth and the 
onset of CH is not well known, these data highlighted the occurrence of non-
inheritable post-zygotic events in the etiology of CH and that environmental risk 
factors may act as a trigger on a susceptible genetic background in the etiology 
of the disease. Supporting this hypothesis, it has been demonstrated that some  
congenital extra-thyroidal malformations affects heart, nervous system, eyes 
(representing precocious structures in the developing embryo) and multiple 
congenital malformations are significantly associated to CH [Passeri et al., JCEM, 
2011; Monroy-Santoyo, 2012]. These findings have strongly suggested a very 
early impairment in the first stages of embryo development with a consequent 
involvement of different organs and structures.  
In this scenario, epigenetic alterations appear to play an important role. Over the 
past decade, there has been increasing evidence supporting the concept that 
adverse factors in the perinatal environment predispose an individual to disease 
later in life [Waterland et al., 2006]. Central to this concept, and driven by the 
initial epidemiological studies of David Barker and colleagues [Barker et al. 
,1993], is the well substantiated link between birth weight and the development 
of a number of adult diseases, including obesity (Herrera et al., 2011), 
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hypertension (Curhan et al., 1996), coronary artery disease (Hiltunen et al., 2006) 
and insulin resistance (Zhao et al., 2012). In other words, adverse intrauterine 
environmental factors, often associated with low birth weight, increase disease 
risk postnatally (Barker et al., 1994; Canani et al., 2011; Lucas, 1991). 
Traditionally, cardiovascular and metabolic disorders including coronary artery 
disease, hypertension and type II diabetes have been thought to be caused by 
lifestyle risk factors acting upon a fixed genetic background.  
However, based on multiple epidemiological studies, the fetal origin of adult 
diseases hypothesis suggests that environmental factors acting early in life play 
an important role in the pathogenesis of these diseases in adulthood (Armitage 
et al., 2004). Exposure to an inappropriate diet or toxins during the 
developmental period is related to aberrant DNA methylation and  adverse 
pregnancy outcomes [Robins et al., 2011] and in exacerbating the risk of disease 
onset [Bloomfield et al., 2011]. The intrauterine environment can affect the 
intake of methyl donors and the establishment of a correct pattern of DNA 
methylation during both in the early phase of fetal development [Rogers et al., 
2011] and the latter stages of pregnancy [Reynolds et al., 2011]. Changes in the 
fetal physiological, neuroendocrine or metabolic environment may result in 
permanent reprogramming of the developmental pattern of cellular proliferation 
and differentiation, resulting in alterations of organ physiology, morphology 
and/or metabolism in adult life. It’s reported that these changes affect the 
development of the kidneys [Woroniecki et al., 2011], pancreatic b-cells 
[Thornburg, 2010], heart [Szostak-Węgierek et al., 2011] muscle [Alexander et 
al., 2011], liver [Hogg et al., 2011], adipose tissue [Lillycrop, 2011] or the 
hypothalamic-pituitary-adrenal (HPA) axis [Seckl et al., 2006].  
 
To our knowledge, we have performed the first case-control study to provide 
evidences of association between DNA methylation and CH onset in premature 
children. We collected a total of 31 infants born premature with normal in situ 
gland and 28 healthy term and preterm controls.  
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The DNA methylation patterns were measured in the genomic DNA isolated from 
peripheral blood lymphocytes. The interpretation of results from methylation 
studies must always be evaluated with caution as epigenetic marks may vary 
depending on cell type and can be influenced by various factors. 
However, some published works have used Illumina Infinium technology to 
assess DNA methylation in peripheral blood lymphocytes and have identified 
CpG sites associated with diseases [Idaghdour et al., 2008; Pedersen et al., 2011]. 
The accumulation of studies that have assessed DNA methylation patterns in 
lymphocytes in multiple diseases and exposures provides evidence that 
methylation patterns in peripheral blood cells may be useful in identifying 
biomarkers of various diseases.  
As previously described in details, to understand the relationship between 
epigenetic changes, prematurity, intrauterine growth and CH onset we 
categorized cases and controls according to 1) gestational age, 2) intrauterine 
growth percentile and 3) TSH level and performed three independent DNA 
methylation studies.  
 
The median global methylation level measured as the %5mC (5-methyl-cytosine) 
in leukocyte-derived DNA, was significantly lower in: 1) CH patients with very 
preterm birth (GA<32 weeks) and preterm birth (32<GA<37 weeks) than term 
healthy controls (37<GA<40 weeks); 2) CH children were born small for 
gestational age (SGA<10th percentile) than AGA controls (10th<AGA<90th 
percentile) and 3) affected subjects with subclinical hypothyroidism (SH, 
4U/ml<TSH<10U/ml) than children with overt hypothyroidism (OH, 
10U/ml<TSH<300U/ml) and preterm and term controls. Based on these early 
results, it seems that the premature birth associated with CH, especially in the 
presence of small intrauterine development is related to global hypomethylation. 
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The findings about the thyroid function approach appear to open novel 
perspectives on the cause of the three to five folds increased risk for mild CH 
with GIS in premature babies. Firstly, if we focus on the clinical data for patients 
with subclinical hypothyroidism, we see that the mean values of gestational age 
and birth weight were significantly lower than other groups. This would explain 
and confirm the hypothesis that the prematurity and the intrauterine growth 
delay, but not the TSH levels, are associated with global hypomethylation. 
Thyroid defects seems to be a secondary event or a co-variate and epigenetic 
modifications may be restricted to only patients with subclinical hypothyroidism 
or mild thyroid dysfunction. So, it’s possible that changes in the DNA methylation 
display a noticeable effect on fetal growth and metabolism, and may be 
sufficient to produce a mild thyroid dysfunction or a resetting of HPT axis 
regulation that can be detected by using low TSH cutoffs for neonatal CH 
screening. Obviously, severe CH would then require additional (genetic?) 
mechanisms to occur. 
Nevertheless, if cases and controls are clustered according to their epigenetic 
profile, infants with overt hypothyroidism showed the most significant 
differences. This suggests that epigenetic changes may directly affect thyroid 
function, but the small number of patients and the influence of potential 
confounders indicate the need for a validation of this interpretation. 
 
These results are confirmed by the gene-specific methylation analysis, where 
approximately 90-96% of DMGs are hypomethylated in affected subjects than 
controls in all the three approaches. To find which factors are related to these 
gene-specific changes, we selected a total of 154 common DMGs and clustered 
all of patients about such genes. We find that affected infants with comparable 
gestational age and low birth weight clusters together unlike those with a proper 
weight. These data are strongly supported by the study of the twin pairs 
discordant or concordant for CH. Interstingly, both concordant and discordant 
112 
 
twins cluster together according to their birth weight unlike their genetic 
similarity and the thyroid disease.  
This allows us to speculate the presence of a direct relationship between the 
gestational age and birth weight with the gene-specific DNA hypomethylation, 
and the increased CH risk could represent an associated co-variate. Interestingly, 
about 75% of these genes are represented by probes located into the DNA non-
coding regions, suggesting that the hypomethylation affects the chromosome 
stability. About the chromosomes distribution of the 154 DMGs, non-CpG island 
sites showed an overestimation than the expected frequencies in chromosomes 
1, 2,3,6,7 and 17, but the reasons and consequences of this stratification remain 
to be clarified. 
In literature, DNA hypomethylation is strongly associated with genomic 
instability and the relationship with developmental growth retardation 
[Koukoura et al., 2011], premature birth [Hofman et al., 2006] and the onset of 
some pathologies in later life such as cancer [Watanabe et al., 2010], dementia 
[Miller et al., 2003], neural tube defects [Chang et al., 2011], congenital heart 
defects [Huang et al., 2007] and diabetes [Toperoff et al., 2012] are reported.  
It acts through the deregulation of transposable elements, pericentromeric 
regions, or activation of endoparasitic sequences. To a lesser extent, DNA 
hypomethylation also impacts growth regulatory genes, imprinted genes, 
developmentally critical genes, genes regulated by transposable elements and 
tissue specific genes, such as germline-specific tumor antigen genes [Raptis et al., 
2006]. DNA hypomethylation patterns also represent footprints of transcription 
factor activities, and therefore are indicative of active cellular pathways. In fact, 
it can thus be used as prognostic indicators of diseases or as predictive markers 
of sensitivity or resistance to particular therapies or environmental exposures 
[Davis et al., 2004].  
Alterations in both global and gene-specific DNA methylation have been linked to 
exposure to metals, peroxisome proliferators, air pollutants, endocrine-
113 
 
disrupting/reproductive toxicants, diet, maternal behavior, viruses, bacteria, 
simulated-microgravity exposure, metabolic imprinting and stress [LaSalle et al., 
2011; Madrigano et al., 2011; Stouder et al., 2011; Pilsner et al., 2011]. More 
closely associated with the early onset of disease hypothesis, global DNA 
hypomethylation in cord blood DNA has been linked to in utero exposure to 
cigarette smoke, polycyclic aromatic hydrocarbons, lead and polyfluoroalkyl 
compounds [Waterland et al., 2008].  
Global DNA methylation changes may also be evolution-conserved adaptive 
responses that maintain homeostasis and assure cell survival in the face of 
threatening and noxious environmental stimuli. Adaptive changes in global 
patterns of differential DNA methylation variability at specific genetic loci can 
also result from inherited genetic variants that predispose demethylating 
phenotypes with selective advantages [Feinberg et al., 2010]. Global DNA 
methylation may be a phenotype of the stochastic adaptation to repeated 
exposures to environmental stressors, which would select for epigenetic 
heterogeneity, and thus the ability of cells to grow outside of their normal milieu 
[Feinberg et al., 2010]. Therefore, changes in global DNA methylation content 
may explain the phenotypic variation described by both Darwinian selection 
forces and Lamarckian evolution development [Handel et al., 2010]. 
 
It is clear that a myriad of factors can affect the global hypomethylation but in 
this study we focused our attention on maternal folate deficiency. Folate-
dependent one-carbon metabolism is a highly polymorphic metabolic pathway 
that regulates the distribution of one-carbon derivatives between DNA synthesis 
(proliferation), and DNA methylation (cell-specific gene expression and 
differentiation). As such, normal functioning of this pathway is essential to 
support the rapid fire shifts between proliferation, differentiation and cell death 
that are essential for normal fetal programming and organogenesis. Inadequate 
enzyme activities and imbalances of substrates and cofactors in one-carbon 
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metabolism, together referred to as the 'methyldietary' constituents, may cause 
homocysteine and S-adenosylhomocysteine accumulation.  
Several studies in both animal models [Ibrahim et al., 2011] and humans 
[Orzechowska-Pawilojc et al., 2009] showed the association between increase in 
plasma total homocysteine and risk of subclinical and overt hypothyroidism.  
In a recent work, a group of hypothyroid rats treated with a folate diet during 
and after receiving PTU showed a better and more rapid response of oxidative 
stress and hypothalamic parameters during restoration of the euthyroid state 
than control animals treated with PTU alone which in contrast had higher levels 
homocysteine during the hypothyroid state (Ibrahim et al., 2011). In humans, the 
treatment of hypothyroid woman with Levotiroxine, display a reduction of total 
plasma homocysteine levels and an improvement in the indicators of cellular 
stress (Cakal et al., 2007). In addition, several experimental studies have shown 
that hypothyroidism affects folate metabolism and the enzymes involved in the 
remetylation pathway of homocysteine. In hypothyroid condition the hepatic 
activity of flavoenzyme - MTHFR is decreased. Thyroid hormone may affect the 
availability of FMN and FAD - necessary for stabilizing MTHFR. An impairment of 
enzyme involved in trans-sulfuration pathway is than suggested. The increased 
serum creatinine level in hypothyroidism probably reflects a reduced glomerular 
filtration rate, which is linked to impaired renal homocysteine clearance and 
hyperhomocysteinemia. 
 
Maternal polymorphic variants, nutritional deficiencies and/or environmental 
exposures that negatively affect availability of one-carbon precursors have been 
associated with increased risk of structural birth defects, chromosomal 
anomalies, schizophrenia, and prematurity [Doolin et al. 2002; Van der Linden et 
al. 2006; James et al. 1999; Johnson 1999; Bukowski et al. 2009; Scholl and 
Johnson 2000; Picker and Coyle 2005]. Defects in Methylenetetrahydrofolate 
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reductase (MTHFR) activity is strongly related to maternal folate deficiency 
during pregnancy [La Merrill et al., 2011]. 
MTHFR is highly polymorphic, and the variant genotypes result in decreased 
MTHFR enzyme activity and lower plasma folate level. Several non-synonymous 
single nucleotide polymorphisms (SNPs) are present in the coding region of the 
gene including positions 677 and 1298. MTHFR enzyme activity is reduced by 
35% among the 677C/T carriers and by 50% to 70% among 677T/T carriers. The 
function of polymorphism 1298A>C has not been consistently demonstrated; 
however carriers of the heterozygous genotypes (677CT/1298AC) show MTHFR 
activity similar to that in MTHFR677T/T carriers. The genetic analysis of nine 
mothers of discordant and concordant twin pairs and CH-only children revealed 
that mothers with the MTHFR677T/T genotypes are those whose affected twins are 
born small for gestational age. Single MTHFR677C/T polymorphisms are found in 
mothers of one AGA discordant twin pairs and two SGA only children. 
MTHFR1298A/C variants are found in mothers of AGA discordant twins, SGA/AGA 
concordant twins and in SGA only child. The MTHFR677C/T, 1298A/C genotype is 
carried by parents of SGA only-child. Although these data have to be extended 
and validated, intrauterine growth delay appears invariably associated with the 
presence of these genetic variants. Maternal folate deficiency caused by MTHFR 
deficiency leads to a shortage of methyl-donors and as a consequence to the 
hypomethylation status. The genomic instability and the altered regulation of 
certain factors potentially affected pregnancy outcomes and fetal growth.  
 
By Gene Ontology and KEEG Pathway databases we have found that several 
genes belong to the biological processes involved in fetal development and 
maintenance the homeostasis of hormone levels. Biological processes such as 
regulation and response to hormone stimulus, post-embryonic development, 
regulation of retinoic metabolism, metabolism of vitamins and sulfur metabolism 
are found to be regulated at the epigenetic level. The most significant signal 
pathways are involved development, in autoimmune thyroid disease and in 
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retinol and glutathione metabolism. The inclusion of these specific processes 
within the top ten most significant gene set overlaps provided evidence of strong 
biological relevance of the differentially methylated genes to fetal development 
and thyroid function. 
If the methylation status of these genes in thyroid gland or TH target tissues 
would be similar to that seen in leukocytes, the altered expression of several of 
these genes (eg, PDEs affecting the sensitivity of thyroid tissue to TSH stimulation 
or retinoic acid signal cooperating at the hypothalamic-pituitary level with that of 
TH in the negative feedback mechanism) may affect the setting of the HPT axis 
function.  
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CHAPTER VIII 
7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This project sheds light for the first time on the possible involvement of 
environmental factors in predisposition to congenital hypothyroidism. The 
results obtained, although they are preliminary, indicate a direct relationship 
between hypomethylation and low gestational age and birth weight in 
hypothyroid infants. The findings about the involvement of DMGs in 
development, metabolism and hormone action, are in agreement with the 
DOHaD theory (fig 27).  
 
 
 
Figure 28: representation of DOHaD theory.  
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We suggest that several environmental factors, such as maternal nutrients 
deficiency or toxins exposures caused a global hypomethylation of fetus. Low 
methylation levels of non-coding regions affect chromosomes stability that is 
strongly associated to prematurity and low birth weight. Rather, stochastic 
hypomethylation of promoters of specific genes can explains the early 
adaptation of fetus of the extrauterine life.  In fact, it’s demonstrated that the 
fetus when exposed to metabolic, nutritional or hormonal deficiencies, adapts by 
increasing the expression of specific genes, such as hormone receptors or growth 
factors to overcome this condition even during the postnatal period. This 
adaptation is a double edged sword since although it is an advantage during fetal 
development, this leads to permanent alterations in sensitivity to internal and 
external stimuli and this kind cell memory predisposes newborns of further 
diseases in adulthood. In light of this evidences, congenital hypothyroidism may 
be caused not only by an abnormal development due to prematurity and low 
birth weight but also to the an altered sensitivity of cells of thyroid hormones to 
adapts on the intrauterine deficiency of nutrients and on the reducing maternal 
metabolism . This stable and altered cellular response to hormonal stimuli may 
explain the higher risk of premature infants of CH and elucidated why these 
patients do not have increased levels of methylation after treatment with L-
thyroxine.  
 
To validate this hypothesis we aim to: 
 Increase the number of CH patients  and make a new methylation analysis 
to confirm the association with hypomethylation and GA and BW; 
 Analysis of global and the gene-specific methylation on the DNA extracted 
from hair follicles in the patients included in this study to confirm that 
PBMCs are a good model for studying thyroid diseases.  
 Assess the levels of expression by Real Time PCR of selected genes list to 
view if they correlate with the DNA methylation levels. 
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If confirmed by further experiments, our results could propose that folic acid can 
be used as an adjuvant therapy in neonatal mild thyroid dysfunction in 
association with or in alternative to thyroxine replacement therapy.  
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